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Abstract 
 
Introduction: The prevalence of obesity is rising and maternal obesity 
has been implicated as a perpetuating factor. Maternal obesity has been 
linked to the development of macrosomic neonates who are at increased risk 
of becoming obese themselves. Current understanding of the mechanisms 
instigating this are unknown, however the pro-inflammatory status 
associated with obesity has been suggested. 
 
Method: Anthropometric estimation of fat mass and percentage body fat 
was conducted on neonates of lean and obese women and their placentae 
analysed for morphological changes by light microscopy. Placental explants 
from both cohorts of women were incubated in order to determine the 
regulatory role of glucose, leptin, tumour-necrosis factor-α (TNF-α), and 
insulin on the production of interleukin-1 (IL-1β), interleukin-6 (IL-6), 
and TNF-α. 
 
Results: Neonates of obese mothers were found to have increased birth 
weight, fat mass, fat free mass, and percentage body fat in comparison to 
neonates of lean mothers. The rise in birth weight, fat mass, fat free 
mass, and percentage body fat were not shown to significantly correlate to 
maternal booking BMI on univariate analysis. Placentae of obese women were 
shown to produce more IL-6 under basal conditions and in response to TNF-α 
stimulation. Glucose was shown to reduce placental production of IL-1β, 
IL-6, and TNF-α in both cohorts, and leptin and insulin stimulation had no 
effect on cytokine production. There was no evidence of placental 
inflammation on examination by light microscopy. 
 
Conclusion: Maternal obesity is associated with neonates of 
increased birth weight and adiposity, and increased production of 
inflammatory mediators by the placenta which is not evidenced in overall 
placental appearance. It is hoped that by elucidating the mechanisms by 
which obesity may be perpetuated, via the in-utero environment for 
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example, foundations for future research can be established which are 
aimed at tackling the epidemic of obesity.  
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Chapter 1: Introduction 
1.1. Obesity: 
1.1.1. Defintion: 
Obesity develops when the energy intake of an individual is greater than 
their energy expenditure and, in adults, is defined by a body mass index 
(BMI) of greater than, or equal to, thirty1. In children, obesity is 
defined as having a BMI of greater than the 95th percentile based on UK 
age-specific reference population charts2. BMI is a simple weight-for-
height index and is the most commonly used calculation for determining if 
an individual’s weight is ideal. BMI is calculated by dividing weight in 
kilograms (kg) by height in metres squared (m2). The classification system 
for BMI is listed in the table below3: 
 
Calculated BMI (kg/m2) Classification 
>18.5 Underweight 
18.5-24.9 Ideal Weight 
25-29.9 Overweight 
30-39.9 Obese 
>40 Morbidly Obese 
Table 1.0 – Classification of BMI 
 
These classifications are benchmarks for individual assessment and are not 
a direct correlation of overall adiposity. Two individuals with the same 
BMI are unlikely to have the same degree of fat mass. BMI does, however, 
provide a useful measure of obesity within the population as the same 
calculation is used for both sexes and all ages.  
1.1.2. How Big a Problem is Obesity? 
In 2008, the World Health Organisation (WHO) estimated that over 500 
million adults worldwide were obese4. More worryingly, in 2010 the WHO 
estimated that at least 43 million children under the age of five years 
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were overweight. Their projections for the future are also ominous, with 
an estimated 700 million obese adults worldwide by 2015. Originally 
obesity was confined to high-income, developed countries however it is now 
becoming an increasing problem in low-income developing countries4. 
 
The picture for the United Kingdom (UK) is no better. In 2007, the Health 
Survey for England reported that amongst adults aged 16 years and over, 
24% of men and women were obese, a rise of 11%, and 8%, respectively5. 
And, among boys and girls aged 2-15, 17% of boys were obese and 16% of 
girls were obese.  By 2050, it is predicted that 60% of adult men, 50% of 
adult women and 25% of children will be obese. This trend is mirrored in 
other EU countries, but the UK rates are some of the highest5.  
 
The principal problem with obesity is the multitude of morbidities that 
are associated with it, and the list appears to be ever increasing, 
including such ailments as cardiovascular disease, diabetes mellitus, 
hypertension, stroke, and certain cancers6.  
 
Figure 1-1 - Schematic diagram illustrating the clustering of morbidities 
associated with obesity
7
. 
It is believed that; 58% of type 2 diabetes mellitus; 21% of coronary 
heart disease; and between 8% and 42% of certain cancers (mainly 
endometrial, colon, and breast); are attributable to excess body fat8. Not 
only are there severe health implications associated with obesity but 
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there are many social disadvantages too. Many obese people are stigmatised 
and bullied, resulting in depression and low self-esteem2. 
 
As a result of the associated morbidities, obesity has been shown to 
reduce life expectancy by, on average, 9 years9. Each year in the UK, 
approximately 9000 premature deaths occur as a result of obesity, far 
exceeding the mortality rates of any other common disease9. Some recent 
data even suggests that, in the UK, obesity is responsible for up to seven 
percent of all morbidity and mortality10.  
 
In order to prevent increasing obesity-related mortality, the treatment of 
the associated morbidities falls to the NHS. In 2007, the direct cost of 
obese and overweight patients on the NHS was calculated at £3.23 billion, 
representing 5% of the total NHS budget11. This figure is set to double by 
the year 2050. The cost to the economy as a whole, including money lost 
through sick days or disability allowance, was £16 billion in 2007, and 
that is also set to rise to a staggering £50 million by 205011. 
 
Obesity rates are rising worldwide, and currently, no country has managed 
to reverse this trend. In the modern world, fuelled by high-fat, high-
sugar convenience food, our ability to store surplus energy, which was 
evolutionary developed to help withstand famine, has undoubtedly led to 
one of the biggest epidemics to ever face this planet7. Obesity threatens 
to jeopardise, not only the health and well-being of millions of people 
worldwide, but also the economic stability of their countries. It is 
imperative that the determinants of obesity and its associated morbidities 
are understood. Without doing so, therapeutic modalities to target obesity 
and prevent further escalation will be unable to be developed. 
 
To elucidate all the determinants of the metabolic pathologies associated 
with obesity is beyond the scope of this thesis. Primarily, the literature 
review will focus on inflammation as a key mediator in the development of 
certain metabolic pathologies. Focus will then be paid on how this 
inflammatory state could potentially be conveyed to the in-utero 
environment, and how this may alter foetal growth. 
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1.1.3. Adipose tissue: 
In humans, there are two forms adipose tissue, white and brown12. Brown 
adipose tissue is found mainly within the thorax and derives its’ colour 
from rich vascularisation and densely packed mitochondria. Brown adipose 
tissue is of particular importance in neonates for body temperature 
regulation by thermogenesis12. 
 
Most excess energy is stored as triglycerides in white adipose tissue 
(WAT). The triglycerides are stored as a buffer for when energy intake 
does not match energy output and can be released as free fatty acids and 
glycerol12. Storing energy as triglycerides is an efficient storage of 
energy as one gram of fat can generate 9 kilocalories compared to one gram 
of carbohydrate or protein which only generates 4 kilocalories13. 
 
Until recent years, it was assumed that the only role of WAT was energy 
storage, and thermal and mechanical insulation14. However, WAT has now been 
recognised as a highly active endocrine organ, secreting several major 
hormones, principally leptin and adiponectin, and a range of other protein 
factors, which are now collectively known as ‘adipokines’14. Currently, 
over fifty adipokines have been recorded, and their functions have been 
described by categorising them into groups: 
 
Category / Function of Adipokine Examples of Adipokine within each Category 
Classical cytokines Tumour necrosis factor-α (TNF-α), Interleukin-6 
(IL-6), Interleukin-8 (IL-8) 
Growth factors Transforming growth factor-β 
Alternative complement system Adipsin, Acylation-stimulating protein 
Vascular haemostasis Plasminogen activator inhibitor-1 (PAI-1), Tissue 
factor 
Regulation of blood pressure Angiotensinogen 
Lipid metabolism Retinol-binding protein 
Glucose homeostasis Leptin, Adiponectin, Resistin 
Angiogenesis Vascular endothelial growth factor (VEGF) 
Acute-phase and stress responses Haptoglobin, Metallothionein 
Table 1.1 - Table to show categories and functions of adipokines secreted by 
WAT
14
.
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Even without specifying any detail, it is clear by just looking at Table 
1.1 that WAT secretion of adipokines has widespread effects. Therefore, it 
is not surprising that when there is relentless nutritional overload, and 
excess WAT is accumulated, many physiological processes become 
asynchronous, disrupting homeostasis and resulting in metabolic 
abnormalities. Obesity is characterised by the following physiological 
changes: 
 
1.1.4. Hyperleptinaemia: 
Due to the excessive volume of adipose tissue, obesity is associated with 
hyperleptinaemia and leptin resistance15. Leptin is a 16-kDa polypeptide 
hormone, and is primarily synthesised by adipose tissue and is coded for 
by the obese (ob) gene15. The production and secretion of leptin is 
positively correlated with adipocyte volume and number, such that larger 
adipocytes produce more leptin than smaller adipocytes, explaining why 
leptin levels are elevated in obesity16.  
Leptin exerts is biological actions through interaction with its specific 
surface receptor, OB-R15. The OB-R receptor mediates leptin action by 
activation of a multitude of divergent signal transduction pathways and 
transcription factors, including mitogen activated protein kinase (MAPK), 
nuclear factor-ĸB (NF-ĸB), and peroxisomal proliferator-activated 
receptor-γ (PPARγ)15. 
The primary function of leptin is to act locally, and centrally, co-
ordinating metabolism and nutrient availability17. When nutrients are in 
excess and adipocytes are saturated, leptin acts as a satiety factor in 
the hypothalamus to suppress appetite and increase energy expenditure18. In 
order for leptin to exert its effects on the hypothalamus, it must first 
be transported across the blood-brain barrier by a transporter19. When high 
leptin plasma concentrations are reached, this transporter becomes 
saturated and its ability to transport leptin becomes impeded19. This leads 
to decreased suppression of appetite, which subsequently leads to 
excessive food intake18. This then increases the volume of adipose tissue, 
leading to increasing hyperleptinaemia, escalating the problem further. 
Thus, hyperleptinaemia is associated with a decreased energy homeostasis18. 
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Leptin has also been found to interact with insulin, in what is termed the 
‘Adipoinsular Axis’20. Insulin has an adipogenic effect on adipocytes, 
increasing energy storage, which is an unwanted process if nutrients and 
energy storage are already in excess. Therefore, leptin exerts an 
inhibitory effect on pancreatic β-cells and reduces insulin secretion 
which, in turn, prevents further energy storage within adipose tissue. The 
same process is also thought to work in reverse; as adipose stores 
decrease so too does leptin production, which then permits an increase in 
insulin production, and thus, increases the deposition of adipose stores20. 
 
Figure 1-2- Schematic diagram of the Adipoinsular axis 
Therefore, it is not hard to see how, if leptin levels were elevated, 
insulin secretion from the pancreas would be inhibited leading to 
disturbed glucose homeostasis leading to the development of 
hyperglycaemia.  
 
Another adipokine, known to be altered in obesity, and which is also 
important for glucose homeostasis and insulin sensitivity is adiponectin. 
1.1.5. Decreased Adiponectin Levels: 
Adiponectin is a 30-kDa protein, which was thought to be produced, and 
secreted, exclusively by adipocytes21. Recent data now suggests that other 
cell types may contribute to adiponectin production; however the specific 
cell types involved is currently unknown. Apidonectin exerts its actions 
through two main receptors; AdipoR1, and AdipoR222. AdipoR1 and AdipoR2 
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have been shown to increase AMP kinase (AMPK) and PPARα activity, 
respectively. This activation leads to increased insulin sensitivity 
through fatty acid oxidation and increased glucose uptake. AdipoR1 has 
been shown to be present in the hypothalamus and increased AMPK activity 
is linked to increased food intake22.  
 
It would therefore appear that leptin and adiponectin work as antagonists 
of one another. When adipose stores are high, leptin is secreted 
decreasing insulin sensitivity, and food intake. And when adipose stores 
are low, adiponectin is secreted increasing insulin sensitivity, and food 
intake. One could therefore assume that the two hormones work in synchrony 
to maintain an appropriate level of food intake and energy storage22. This 
assumption is further supported by the fact that circulating plasma 
concentrations of adiponectin are inversely related to circulating plasma 
concentrations of leptin19. Therefore, as circulating leptin levels rise 
with increased adiposity, adiponectin levels fall19. Decreased adiponectin 
levels then lead to diminished insulin sensitisation, and coupled with the 
effects of leptin, insulin resistance and hyperglycaemia ensue. For this 
reason, both hyperleptinaemia and decreased adiponectin, are positively 
associated with the development of insulin resistance and type 2 diabetes 
mellitus12. 
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1.1.6. Chronic-Low Grade Inflammation: 
An important and recent development is the finding that obesity is 
characterised by chronic, low-grade inflammation23. The term ‘low-
grade’ inflammation is used to distinguish this type of 
inflammation, found in obesity, from the classical inflammation 
found in response to injury. Rarely are the classical symptoms, such 
as redness, swelling, pain, and fever, associated with obesity-
induced inflammation. Although some of the same mediators and 
pathways are used, it must be made clear that the acute inflammation 
seen in response to injury or infection is very different to the 
long-term inflammation witnessed in obesity7. Obese individuals have 
been reported as having increased circulating levels of the pro-
inflammatory factors TNF-α, IL-6, IL-8, and IL-18, and increased 
circulating levels of the acute-phase proteins C-reactive protein 
(CRP) and haptoglobin23. 
1.1.6.1. Acute Phase Proteins: 
Other acute phase proteins, mainly pro-coagulant proteins, known to 
be positively correlated with obesity are tissue factor, PAI-1, and 
factor VII16. Synthesis of PAI-1 has been shown to originate from 
within WAT, however the source of the other factors is less clear. 
PAI-1 is a crucial factor in the maintenance of vascular 
homeostasis, inhibiting the action of plasminogen, the precursor of 
plasmin, thus inhibiting the degradation of fibrin. Together, with 
the other pro-coagulant proteins, raised PAI-1 levels permit fibrin 
accumulation, resulting in atherothrombotic disease. This clearly 
demonstrates how one of the morbidities associated with obesity can 
be directly linked to alterations in adipokine production, secondary 
to the increased fat mass14.  
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However, the biggest problem associated with obesity, is the raised 
levels of pro-inflammatory proteins as they have widespread effects 
on multiple physiological processes. 
1.1.6.2. Pro-inflammatory Markers: 
Circulating TNF-α levels are raised in obesity, and although TNF-α 
is expressed in, and secreted by, adipocytes, the vast majority of 
TNF-α is secreted by cells of the stromal vascular and matrix 
fractions, including macrophages16. The extent to which adipocytes 
contribute to the elevated circulating levels of TNF- α is still 
under debate. It should be noted, that in lean individuals WAT has 
not been identified as a major source of TNF-α.  
TNF-α is said to act as an influential local regulator, stimulating 
many processes including apoptosis24. It also acts as a regulatory 
factor in the production of other adipokines, mainly IL-6, which is 
also secreted by adipocytes. In obesity, IL-6 circulating levels are 
also elevated, which has been attributed to WAT secretion secondary 
to the finding that IL-6 gene expression is increased within WAT of 
obese individuals. The functional role of IL-6 in obesity is 
unknown, however IL-6 receptors have been found within the 
hypothalamus, indicating that it may exert direct central actions24. 
Therefore, in addition to leptin, IL-6 may contribute to energy 
regulation by conveying information from adipocytes to the 
hypothalamus14.  
TNF-α has also been shown to stimulate IL-8 release and, once again, 
increased gene expression has been found in WAT suggesting it is the 
source for raised IL-8 levels in obesity14. IL-18 has also been found 
to be raised in obesity, and levels have been shown to decline with 
weight loss, leading to speculation that it also originates from 
WAT; however this has yet to be proven14. 
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A key question, which remains to be fully answered, is what is the 
source of the raised pro-inflammatory cytokines? Current research 
speculates that there are three possibilities: 
1. The inflammatory markers originate from a source other than 
adipose tissue, primarily the liver and the cells of the 
immune system14; 
2. The inflammatory markers originate from an alternative source 
but are stimulated to do so by factors secreted by the WAT 
e.g. hepatic production of CRP is known to be increased in 
response to IL-6 secretion from the expanded WAT14; 
3. The inflammatory markers originate from within the adipocytes 
themselves and the increased plasma levels are ‘spill over’ 
from the overall increased adipose mass14. 
The most prevalent hypothesis is that the excess WAT initially 
produces excess cytokines which subsequently leads to the 
stimulation of cytokine production by immune cells which have been 
recruited to the WAT7. In the context of obesity, WAT is known to 
contain macrophages, and macrophage precursor cells; however what is 
not known is why the macrophages are initially recruited7. 
Several theories propose that in the obese individual, adipocytes 
begin to secrete low levels of TNF-α which, in turn, stimulates both 
pre-adipocytes, and endothelial cells, to produce monocyte 
chemoattractant protein-1 (MCP-1), leading to the recruitment of 
macrophages7.  Research in mice, has suggested that the initial 
cytokine secretion by the adipocytes may be as a consequence of 
hypoxia14. Research has shown that as obesity progresses and fat mass 
increases, the supporting vasculature is overwhelmed with the 
increased metabolic demands leading to oxidative injury of the 
vasculature and hypoxia within the cells. The hypoxic adipoctyes 
then respond by secreting inflammatory markers, such as TNF-α and 
IL-1β, in an attempt to stimulate angiogenesis. This, in turn, then 
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activates transcription factors, such as hypoxic-inducible factor-1 
(HIF-1) within the adipocytes, and stromal vascular cells14. HIF-1 
then targets the genes encoding for vascular endothelial growth 
factor (VEGF), plasminogen activator inhibitor-1 (PAI-1) and leptin. 
This then leads to altered angiogenesis and an increase in blood 
supply14. 
In addition to the altered angiogenesis, hypoxia also induces 
necrotic death of large numbers of adipocytes18. It should be noted 
that necrosis-like death is the primary method of cell death in WAT, 
opposed to apoptotic cell death, and unlike apoptosis, necrotic 
cells die in an uncontrolled manner, requiring macrophages to engulf 
the necrotic debris. Therefore, inflammatory mediators, such as MCP-
1, are released by the necrotic cells18. MCP-1 secretion coupled with 
TNF-α and IL-1β secretion, leads to large numbers of macrophages 
being recruited into adipose tissue, which also adhere to the 
endothelial cells23. It is presumed that macrophage recruitment, in 
this case, would be for phagocytosis of the necrotic adipocytes23.  
However, there are also some alternative theories about macrophage 
recruitment into WAT. Other research, in mice and humans, has shown 
that there is increased macrophage gene expression directly 
proportional to body weight, suggesting that macrophage content of 
adipose tissue is correlated to adiposity and BMI16. Accumulation of 
macrophages within the WAT increases as adipocyte volume increases, 
and along with BMI, can be used as a predictor for macrophage 
numbers within WAT16. In this instance, the role of the macrophages 
may be to act as a paracrine messenger between enlarged adipocytes 
whose function has become altered as a result of obesity16. Other 
research has suggested that the macrophages infiltrate the adipose 
tissue first and that the ensuing inflammatory response is a direct 
result of the invading macrophages23. However, their initial stimulus 
for invasion, and/or their function within the WAT, has not 
specified, and therefore, these remain rather inconclusive theories. 
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Nonetheless, regardless of their function, or the initial 
recruitment stimuli, these recruited macrophages, along with the 
adipocytes, are integral to the production of the pro-inflammatory 
cytokines associated with obesity23. The initial macrophage 
recruitment culminates in a vicious cycle of increased cytokine 
production leading to increased macrophage recruitment23. Adipocyte 
dysfunction is disturbed further with exacerbated alterations in 
gene expression, mainly related to metabolic and inflammatory 
pathways, leading to an overall worsening inflammatory and metabolic 
status of the obese individual23. 
 
Figure 1-3 - Diagram to illustrate perpetuating cycle of macrophage recruitment 
and increased production of pro-inflammatory cytokines.
23 
Metabolic dysfunction is mainly instigated by the profound 
inhibitory effects the pro-inflammatory cytokines, especially TNF-α, 
have on insulin sensitivity and action25.  
Initiation of the insulin signalling pathway is induced by insulin 
binding to an insulin receptor (IR), resulting in receptor auto-
phosphorylation and, subsequent phosphorylation of IR substrates 
(IRS)25. IRSs, in turn, associate and activate down-stream effectors 
which ultimately have the ability to regulate, and induce, end-point 
glucose transporters25. 
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TNF-α has been shown to promote serine phosphorylation of IRS-1, 
impairing its association with the IR, inhibiting insulin 
signalling, and insulin-regulated glucose uptake25. Ultimately this 
mediates an insulin resistant state. Research has proven that when 
exogenous TNF-α is administered to obese humans, the development of 
insulin resistance is promoted25. There is also evidence 
demonstrating that obese mice with non-functioning TNF-α have 
improved insulin sensitivity and better glucose homeostasis26. These 
findings support the theory that TNF-α, and the activation of 
inflammatory pathways, are critical for the regulation of insulin 
action in the obese individual. Whether TNF-α is solely responsible 
for the effect on insulin action, or it is the inflammatory 
pathways, remains to be discovered7. TNF-α and IL-6 have also been 
implicated in the development of hypertriglyceridaemia and raised 
serum fatty acid concentration which is thought to originate by 
stimulating lipolysis and increased hepatic triglyceride secretion27. 
Cumulatively, all these disturbances in adipokines, including: 
leptin, adiponectin, TNF-α, and interleukins; leaves the obese 
individual exposed to perturbations in glucose and triglyceride 
homeostasis, and alterations in blood coagulation. Thus, as a direct 
result of increased WAT obese individuals are predisposed to the 
development of hypertriglyceridaemia, insulin resistance, and 
atherothrombotic disease7.  
The physiological changes documented by no means explain all of the 
associated morbidities with obesity but they do go part way to 
explaining the origins of the clustering of metabolic diseases 
surrounding obesity. This ‘clustering’ of diseases has subsequently 
been termed, ‘Metabolic Syndrome’ and is said to encompass: obesity, 
insulin resistance, glucose intolerance, hypertriglyceridaemia, low 
high-density lipoprotein (HDL) cholesterol, hypertension and 
accelerated atherosclerosis28. Individuals with metabolic syndrome 
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are at increased risk of type 2 diabetes mellitus and cardiovascular 
disease7. 
What is intriguing is that over the past few decades, it has been 
noticed that these metabolic pathologies are beginning to emerge in 
children. In 2000, the first cases of type 2 diabetes mellitus were 
reported in overweight girls aged nine to sixteen29. There are now 
approximately 1,400 children diagnosed with type 2 diabetes mellitus 
in the UK29.  
One factor believed to be involved in the increasing incidence of 
metabolic pathologies in children is maternal obesity30. 
Epidemiological data has indicated that the intrauterine period is 
one of vulnerability, and if present, a suboptimal intrauterine 
environment, such as the chronic low-grade inflammation associated 
with obesity, has the potential to jeopardise the long-term health 
of the foetus30. Barker et al coined the phrase, ‘foetal origins of 
health’, to describe the molecular and physiological changes that 
can occur in foetal tissue secondary to an early in-utero event, or 
ongoing environment such as obesity, leading to altered growth31. 
1.1.7. Metabolic Syndrome and its Link with Maternal Obesity: 
Longitudinal studies have proven that maternal obesity is a risk 
factor for the development of metabolic syndrome in offspring32. 
Neonates whose birth weights are greater than, or equal to, the 90th 
centile are said to have the greatest risk of developing metabolic 
syndrome in later life33. One study reported that infants of obese 
mothers were two and a half times more likely to be obese at 2-4 
years of age when compared to infants of lean mothers34.   Whether 
this trend could be attributed to the postnatal environment was not 
commented upon and therefore could be an contributing factor to this 
finding.  
Several studies have shown that there is a positive linear 
relationship between maternal BMI and neonatal birth weight35. 
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Catalano et al stated that, over the past thirty years there has 
been a mean increase in birth weight by 116g in term singleton 
pregnancies, and that maternal weight at delivery correlated most 
strongly with this increase36. This is in conjunction with other 
studies conducted in North America and Europe, which also reported a 
correlation between maternal obesity and increased birth weight37,38. 
Studies have shown that much of the variability in birth weight of 
neonates can be accounted for by the volume of adipose tissue 
present39. Foetal lean mass has been shown to remain relatively 
constant, even between small-for-gestational-age (SGA) and large-
for-gestational-age (LGA) foetuses, and changes in a consistent 
manner over time40. This is unlike foetal fat mass which vary 
significantly between neonates30. Neonates of obese mothers when 
compared to neonates of lean mothers have been shown to have 
significantly increased fat mass and percentage body fat30. Studies 
have also demonstrated that neonates of obese mothers have a raised 
ponderal index41. Ponderal index is a neonatal anthropometric measure 
of obesity, which is the equivalent to BMI in adults, and is 
calculated by birth weight (kg)/length3 (m3)42. Thus neonates of obese 
mothers are not only more likely to be heavier, but they are also to 
be more obese. 
There is even some evidence to suggest that metabolic compromise is 
apparent before birth41. In a cohort study of fifty three lean and 
sixty eight obese women, Catalano et al measured the umbilical cord 
concentrations of insulin, glucose, leptin, and IL-6. They reported 
that the neonates of the obese women had higher fasting cord levels 
of insulin, glucose, and leptin, and concluded that the neonates 
were more insulin resistant than their lean counterparts. The 
neonates were also found to have increased adiposity which 
positively correlated to the level of insulin resistance. Insulin 
resistance was also reported to be positively correlated to maternal 
pre-gravid BMI. This study, therefore illustrates a link between 
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maternal pre-gravid BMI and the development of foetal metabolic 
compromise in utero, and the importance maternal pre-gravid BMI has 
on foetal development41. 
 
Maternal weight gain during pregnancy has also been highlighted as 
an important factor associated with neonatal birth weight. Rossner 
and Ohlin studied the relationship between birth weight, initial 
maternal weight, and total maternal weight gained during pregnancy 
of 2,295 women of varying BMI in Stockholm43. Total maternal weight 
gain was shown to be the strongest predictor of birth weight, 
followed by initial maternal weight. This positive correlation was 
only demonstrated up until a BMI of 24kg/m2, which after this point 
the strength of association decreased43.  
This somewhat confuses the literature as this finding would indicate 
that maternal obesity is not positively associated with a rise in 
birth weight. However, this may be explained by the fact that 
maternal obesity is not only associated with macrosomic neonates but 
also SGA neonates44. Maternal obesity has been implicated in the 
development of both macrosomia and SGA neonates and, interestingly, 
both groups are at increased risk of developing metabolic syndrome45. 
To date, the literature does not yet have any definitive evidence 
specifying the patho-physiology linking the development of these two 
neonatal outcomes to maternal pre-gravid obesity and also to the 
subsequent development of metabolic syndrome46. 
Before proceeding, it is important the some definitions are 
clarified. Macrosomia is classified as a birth weight of greater 
than 4000 grams, irrespective of gestational age47. Whereas, LGA is 
typically defined as a birth weight greater than or equal to the 90% 
centile on a birth weight centile chart48. The terms appear to be 
used interchangeably and are both associated with multiple obstetric 
and neonatal problems. Therefore, it was decided that the term 
macrosomia will be used throughout this thesis.  
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For the purposes of this thesis, the literature review will explore 
the impact of maternal obesity and its associated chronic low-grade 
inflammation on placental function and foetal development, focusing 
primarily on the mechanisms leading to macrosomic term neonates, and 
possibilities linking this to the development of metabolic syndrome. 
1.1.8. Placental Factors Implicated in Foetal Growth and Alterations 
Related to Maternal Obesity: 
Pregnancy is a natural state of inflammation and altered metabolism 
which is critical for the development of the foetus. When this is 
combined with pre-gravid obesity and its associated metabolic 
dysfunction, an even more disturbed metabolic state is created. 
Obese pregnant women have been shown to have dyslipidaemia, 
hyperinsulinaemia, hyperleptinaemia, cytokine up-regulation and 
impaired endothelial function49. There has been a wealth of studies 
exploring the effect of these metabolic disturbances on pregnancy, 
and foetal outcome, however; the precise full effect is still yet to 
be elucidated. 
Maternal nutrition and metabolism, utero-placental blood flow, 
trans-placental substrate concentration gradient, placental size, 
and its solute transfer capabilities, all affect placental function 
and subsequent foetal growth50. However, as the interface between 
mother and foetus, providing all foetal support, the placenta is one 
of the most important factors governing foetal growth51.  
1.1.8.1. Placental Structure: 
The placenta is a circular discoid organ which is approximately 
twenty two centimetres in diameter and weighs roughly 500grams. 
Morphology of placentae varies greatly and is dependent on a number 
of factors such as delivery mode52. 
The placenta is mainly derived from trophoblastic tissue which 
differentiates from external cells from the morula as it becomes a 
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blastocyst52. Once the blastocyst has attached to the endometrium the 
polar trophoblast differentiates and its mononuclear cells fuse to 
form the syncytiotrophoblast53. 
 
Figure 1.4 – Figure to show formation of the placenta from the blastocyst
53
. 
 
The syncytiotrophoblast then rapidly proliferates invading the 
uterine epithelium cells and at around day twelve the embryo is 
completely implanted53. The remaining mononuclear trophoblastic cells 
are now referred to as the cytotrophoblast, and form a second inner 
circle inside the syncytiotrophoblast. The cells of the 
cytotrophoblast act as stem cells and ultimately fuse with the 
synctiotrophoblast. At around nine days, lacunae form within the 
synctiotrophoblast establishing foetal-placental circulation. 
Maternal and foetal circulations are separated by the 
syncytiotrophoblast and the foetal capillary endothelium52. The 
syncytiotrophoblast which remains in between the lacunae are 
referred to as trabeculae and cumulatively these two sections go on 
to form the villous trees and intervillous spaces of the placenta53. 
The syncytiotrophoblast has two aspects: the microvillous plasma 
membrane (MVM) (maternal aspect) and the basal plasma membrane (BM) 
(foetal aspect)54. And it is through these two membranes that 
nutrient and waste transport from mother to foetus, and vice versa, 
is thought to be regulated55.  
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1.1.8.2. Altered Insulin Sensitivity and Glycaemic Control: 
The ability to regulate nutrient balance during pregnancy is 
critical to maternal and foetal health. In a normal pregnancy the 
placenta secretes a multitude of hormones including; oestrogen, 
progesterone, cortisol, human placental lactogen (HPL), prolactin 
and growth hormone56. These hormones are believed to create an 
insulin resistant state, which has profound effects on maternal 
energy metabolism. In fact, insulin sensitivity is thought to 
decrease by around sixty percent57. This insulin resistant state is 
necessary because, in utero, the foetus primarily relies on glucose 
as its main energy substrate58. As gestation progresses, foetal 
demand increases, and so too does placental hormone secretion, 
decreasing maternal insulin insensitivity further59. Studies have 
shown there is also a thirty percent increase in hepatic production 
of glucose and elevations of blood glucose levels are more frequent 
and pronounced during pregnancy53,60. Obviously these adjustments in 
glucose levels and insulin sensitivity are not completely unopposed 
otherwise this would result in the development of gestational 
diabetes mellitus (GDM). Therefore, there is also an increase in 
endogenous secretion of maternal insulin61.  
This situation however appears to be altered in the context of 
obesity. Non-diabetic, obese pregnant women have been demonstrated 
to have hyperinsulinaemia and they have also been shown to be less 
sensitive, or more resistant, to insulin than overweight, or lean, 
mothers41. As maternal BMI increases insulin sensitivity has been 
shown to diminish41. This may be attributed to the fact that non-
pregnant obese women are initially more insulin resistant than non-
pregnant lean women as a result of hormone and cytokine derangements 
associated with obesity54. The difference in insulin sensitivity is 
most pronounced during early pregnancy, with a less prominent 
difference in late pregnancy54. 
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The decreased insulin sensitivity of obese mothers predisposes them 
to episodes of mild hyperglycaemia. If the episodes were more 
pronounced and long term, GDM would be diagnosed, however not all 
obese mothers are diagnosed with GDM. There are studies to suggest 
that these brief excursions away from euglycaemia may be sufficient 
to induce foetal overgrowth. Ericsson et al induced transient states 
of hyperglycaemia in pregnant rats in early pregnancy, and observed 
that as few as three episodes of transient hyperglycaemia in early 
pregnancy, but not late pregnancy, were sufficient to cause foetal 
overgrowth62. As Catalano demonstrated that insulin insensitivity is 
most prominent in early pregnancy in obese mothers, this seems a 
plausible mechanism for foetal overgrowth. 
Several hypotheses have been suggested with regard to the mechanism 
by which maternal hyperglycaemia may lead to foetal overgrowth. The 
first hypothesis was suggested in 1954 by Pederson63. He observed 
that many women who suffered from GDM during their pregnancies 
produced macrosomic foetuses. He proposed that there must be a link 
between the maternal hyperglycaemia and the development of foetal 
macrosomia63. It was known that placental glucose transfer was 
mediated by facilitated diffusion, and that this was greatly 
dependent upon maternal glucose levels. For that reason, Pederson 
hypothesised that maternal hyperglycaemia could promote increased 
placental glucose transfer, resulting in foetal hyperglycaemia and 
subsequently, foetal hyperinsulinaemia63. This seems a reasonable 
theory for mediating foetal overgrowth, as insulin is known to have 
profound effects on foetal growth patterns, stimulating the growth 
of all foetal tissues except for the brain64. Therefore, foetal 
macrosomia many originate by this mechanism.  
However, foetal macrosomia has also been observed in diabetic 
mothers with strict glycaemic control. If Pederson’s theory were 
absolute then these women, should deliver appropriate-for-
gestational-age (AGA) infants65. This would suggest that 
  
23 
 
hyperinsulinaemia, secondary to maternal hyperglycaemia, is not the 
only mechanism leading to increased foetal growth and fat accretion 
in foetuses of obese/diabetic mothers. 
1.1.8.3. Leptin: 
Another hormone which is known to be elevated in obese pregnancy is 
leptin, which is not surprising given that leptin is raised in the 
non-pregnant obese individual. In fact, leptin levels in obese 
mothers are said to double that of the circulating levels in lean 
mothers41. 
In non-obese pregnancy, leptin is known to peak in the second 
trimester, plateau in the third, and then fall below pre-gravid 
concentration around birth66. Although the rise in leptin could be 
attributed to the increase in adipose tissue gained during 
pregnancy, changes in maternal BMI do not correlate with the 
gestational increase in leptin concentration67. The placenta has been 
shown to mainly secrete leptin into maternal circulation with a 
smaller, but significant, amount being released into the foetal 
circulation. Secretion in foetal circulation is evidenced by higher 
concentrations of leptin in the umbilical vein than the umbilical 
arteries67. There is also a marked postnatal decrease in leptin 
levels in both mother, and foetus, and for that reason the placenta 
has been ascribed as the principal source for raised leptin levels 
experienced during pregnancy68. Within the placenta, leptin mRNA and 
protein is known to be co-localised to the syncytiotrophoblast, and 
cytotrophoblast and appears to be identical to leptin produced by 
adipose tissue; with the only exception being that placental leptin 
has an upstream enhancer, suggesting that its regulation is 
different69. 
Concentrations of leptin within umbilical cord blood have been 
positively correlated with foetal birth weight, length, head 
circumference, and ponderal index, suggesting a regulatory role of 
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leptin in foetal growth70. SGA neonates have been associated with low 
concentrations of circulating and placental leptin, and macrosomic 
neonates of diabetic mothers have been associated with raised 
concentrations of circulating and placental leptin71. One hypothesis 
how leptin may regulate foetal growth is through stimulation of 
amino acid nutrient transporters. Jansson et al cultured primary 
villous fragments from placentae obtained from term, uncomplicated 
deliveries and stimulated them with leptin and insulin. Leptin, in a 
concentration dependent fashion, was shown to increase the uptake of 
an amino acid transporter called System A72.  
System A is widely expressed on the MVM of the syncytiotrophoblast 
and mediates sodium-dependent uptake of neutral amino acids, and is 
implicated in foetal growth73. There are three isoforms of the 
sodium-coupled neutral amino acid transporter (SNAT); 1, 2, and 4. 
These are encoded for by the genes Slc38a1, Slc38a2, and Slc38a4.  
SNAT1 and SNAT2 operate via similar means, whereas SNAT4, has a 
lower affinity for neutral amino acids, and mediates the uptake of 
cationic amino acids74. 
 
As leptin has been proven to stimulate increased transport by system 
A, this poses a possible mechanism for leptin regulation of foetal 
growth. Pregnancies complicated by diabetes, where macrosomic 
foetuses are common, have been shown to have increased system A 
activity.61 Therefore, it would not seem foolish to speculate that 
the raised levels of leptin, present in obesity, might lead to 
increased system A activity and mediate increased foetal growth in 
that manner. However, studies have shown that reality is, in fact, 
to the contrary. 
 
Farley et al conducted similar studies to Jansson et al, but instead 
compared placental system A activity in placentae from seven lean 
and seven obese women75. Placental leptin protein content and leptin 
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receptor expression were also measured. Placentae of obese women, 
with circulating hyperleptinaemia and appropriate-for-gestational-
age infants, were shown to have decreased SNAT 4 activity and 
decreased syncytiotrophoblastic expression of the leptin receptor 
and SNAT 4. In contrast, leptin was found to significantly stimulate 
system A in the placentae of lean women which is in agreement with 
Jansson et al72. Farley et al concluded that due to the increased 
leptin levels in the obese women down-regulation of the leptin 
receptor was precipitated, resulting in leptin resistance76. This 
research would imply that raised leptin levels, in association with 
obesity, are not involved in the up-regulation of system A and 
subsequent foetal overgrowth44. However, this finding may be 
attributed to the fact that the obese women had delivered AGA 
neonates, opposed to macrosomic neonates. It would therefore be 
useful to conduct this study again and examine the effect leptin has 
on system A activity in the placentae of obese women who deliver 
macrosomic infants. Having said that, this study highlights an 
important finding; that placentae from obese women appear to be 
leptin resistant.  
 
Placental leptin has also been implicated in the regulation of 
placental growth during pregnancy77. Umbilical cord concentrations of 
leptin have been shown to correlate with placental size suggesting 
that leptin may act in a paracrine manner stimulating placental 
growth, possibly by angiogenesis; however the precise mechanism is 
unknown78. Studies have demonstrated that there is a positive 
correlation between uncomplicated, full term, singleton placental 
weight and increased maternal BMI79. Therefore, increased placental 
size, secondary to hyperleptinaemia in the obese mother, could 
potentially result in increased nutrient transfer and foetal growth. 
How this is actually mediated, remains to be established. 
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As the intracellular signalling mechanisms are so poorly understood, 
even in lean pregnancy, it is hard to determine whether elevated 
circulating leptin levels have a regulatory role in increased foetal 
growth. The raised levels associated with obesity could simply 
represent an overall increase in placental and adipose mass. 
However, it is possible that leptin is implicated in the regulation 
of cellular tissue growth, opposed to overall foetal growth. In the 
majority of studies examining the regulatory role of leptin, birth 
weight is used as the primary outcome measure, whereas animal 
studies examining specific cells, such as pancreatic islet cells, 
have shown that leptin can induce cell proliferation80. Muhlhausler 
et al conducted studies in sheep and demonstrated that prenatal 
exposure to increased maternal nutrition and hyperleptinaemia during 
late gestation resulted in increased fat deposition in postnatal 
life81. Increased leptin mRNA in perirenal and subcutaneous adipose 
tissue were also reported80. Thus they have demonstrated how maternal 
over-nutrition alters postnatal adipose stores81. More importantly, 
further studies in sheep and non-human primates by Muhlhausler et al 
demonstrated that the nutritional environment to which a foetus is 
exposed in utero and perinatally has long term consequences on the 
function of appetite regulation within the brain affecting its 
feeding behaviour and energy balance throughout its lifetime82. These 
findings illustrate how an infant may be predisposed to obesity in 
later life simply by in-utero exposure to over-nutrition. These 
findings remain to be proven in humans but implicate 
hyperleptinaemia as a potential regulator in determining the 
development of metabolic syndrome in later life. 
This, however, still does not explain how maternal obesity leads to 
foetal overgrowth. Due to the altered levels of cytokines known to 
be associated with obesity, research has therefore explored this 
avenue to see if this sheds any light on the situation. 
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1.1.8.4. Inflammatory cytokines: 
Non-obese pregnancy is associated by raised circulating maternal 
TNF-α levels, which initially decrease during early pregnancy, but 
then increase in late pregnancy55. Like leptin, maternal circulating 
TNF-α levels drop rapidly after delivery and therefore, the rise in 
TNF-α has been ascribed to the placenta83.  
Placental resident macrophages, also known as Hofbauer cells, 
syncytiotrophoblastic cells, and cytotrophoblastic cells have all 
been shown to produce and secrete the following pro-inflammatory 
factors; IL-1β, IL-6 and TNF-α15. The individual contribution of each 
cell line to the cytokine network is difficult to determine due to 
overlapping cell-cell communications. Virtually all cell types 
identified in utero-placental tissues have been shown to participate 
in cytokine networks26. 
The role of pro-inflammatory cytokines in pregnancy is, however, a 
little unclear. Research has implicated some placental cytokines in 
the establishment of pregnancy; IL-1β is known to be implicated in 
implantation.84 One prevalent hypothesis is that these placental 
cytokines contribute towards the alterations in maternal metabolism, 
which is illustrated in Figure 1:4.  
Figure 1-5 - Schematic overview of the production of placental cytokines, and the 
physiological processes they affect
26
. 
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Once villous circulation is established, TNF-α, and IL-6 are 
secreted into the maternal circulation, with a minority entering the 
foetal circulations79. These cytokines could then potentiate 
alterations in maternal metabolism through the mechanisms detailed 
earlier in relation to obesity-induced metabolic changes. However, 
further research is needed to expand upon these hypotheses in the 
context of pregnancy and to detail the precise functional role(s) of 
placental cytokines, and their extra-placental target(s).  
Changes in circulating maternal TNF-α levels have been shown to 
mirror insulin sensitivity changes and, therefore, suggests that 
TNF-α may be a crucial mediator in the development of insulin 
resistance in pregnancy56. Several older studies positively 
correlated changes in insulin sensitivity to placental secretion of 
human placental lactogen (HPL), progesterone and oestrogen56. 
However, although these hormones are increased during pregnancy, 
they have now been shown to have very little predictive power for 
insulin sensitivity85. More recent studies have shown that, in women 
with normal glucose tolerance (NGT), and women with GDM, TNF-α is a 
greater predictor of insulin resistance55. Women with GDM were found 
to produce more TNF-α than women with NGT, however whether TNF-α is 
the sole contributor leading to increased insulin resistance in the 
development of GDM is unknown86.  
Having said all that, it is therefore intriguing that studies have 
reported no differences in the level of circulating TNF-α between 
obese and lean pregnancies87. This is surprising given that in the 
non-pregnant state, obese women are known to have elevated 
circulating levels of TNF-α87. This is also surprising given that 
circulating TNF-α is a strong predictor of insulin insensitivity, 
and therefore, one would expect levels to be raised in the more 
insulin resistant, obese pregnant women87. The finding that maternal 
circulating TNF-α levels are similar in lean and obese women 
suggests two things; firstly, there must be other factors implicated 
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in mediating insulin resistance in the obese mother, and; secondly, 
that maternal circulating TNF-α is not implicated in the development 
foetal overgrowth in the context of obesity. 
However, in a study investigating the placentae of obese neonates 
TNF-α has been implicated in foetal overgrowth. Varastehpour et al 
studied the placentae of eight obese and seven lean neonates 
following elective caesarean delivery88. Obesity in a neonate was 
defined as having greater than 16% body fat. Placentae of obese 
neonates were shown to contain increased TNF-α, and leptin, mRNA 
expression and protein content88. They found that the increased TNF-
α, and leptin, induced increased gene expression of the secretory 
phospholipase A2 (sPLA2) groups IIA, and V88. The PLA2 family is a 
group of lipolytic enzymes that catalyses the hydrolysis of membrane 
phospholipids, releasing arachidonic acid (AA), docosahexaenoic acid 
(DHA), and other polyunsaturated fatty acids (PUFA)88. It was 
suggested that the increased gene expression of sPLA2 led to 
increased generation of PUFAs which can serve as substrates for 
adipogenesis. PUFAs can also amplify local inflammation within the 
placenta which can cause alterations in the phospholipid bi-layer, 
increasing membrane fluidity, and ultimately materno-foetal nutrient 
transfer88. Varastehpour et al demonstrated that accumulation of 
omega-3 fatty acids within the placentae was strongly associated 
with high neonatal adiposity. Therefore, the authors proposed that 
up-regulation of sPLA2 by TNF-α and leptin was a mechanism for 
increased fat accretion and the development of obesity in-utero88.  
This is in contrast to Farley et al’s findings that leptin gene 
expression is decreased in the placentae of obese women75. However, 
these two studies differ as Varastehpour et al examined the 
placentae of obese neonates, and Farley et al examined the placentae 
of obese women with AGA neonates. It would therefore appear that in 
neonates which are obese, TNF-α and leptin are increased within the 
placentae and are implicated in foetal growth, but AGA neonates with 
  
30 
 
obese mothers have decreased leptin gene expression within their 
placentae which is not implicated in growth. It remains to be 
established what the protein content and gene expression of leptin 
and TNF-α is in the placentae of obese mothers who deliver 
macrosomic infants. 
Maternal obesity during pregnancy has, however, been associated with 
increased circulating levels of IL-6, in comparison to lean pregnant 
women, which have been positively correlated to foetal adiposity at 
birth. In experiments conducted on rats, exogenous IL-6 was 
administered during pregnancy and the offspring were found to have 
increased fat accretion, and reduced insulin sensitivity, 
implicating IL-6 as a regulatory factor of foetal growth89. 
Jones et al have demonstrated, in cultured human primary trophoblast 
cells, that physiological concentrations of IL-6 and TNF-α had a 
pronounced stimulatory effect on the activity of system A74. Doses of 
IL-6, similar to the physiological levels seen in obesity, were 
shown to mediate the activation of the signal transducer and 
activator of transcription 3 (STAT3), leading to increased gene and 
protein expression of the system A isoform SNAT274. TNF-α was shown 
to mediate increased protein expression of SNAT1 and SNAT2, however, 
without altering STAT3 signalling or SNAT1 gene expression. STAT3 
has not been previously identified as a cellular mediator in the 
regulation of system A nutrient transport. Unlike leptin, neither 
TNF-α, nor IL-6, had any effect on the expression of SNAT4. The 
authors also reported, in unpublished data, that SNAT2 appears to be 
increased, whereas SNAT4 remains unchanged, in the placentae of 
obese women who deliver macrosomic infants74. However, as TNF-α is 
not raised in obese pregnancy it is unlikely that this mechanism is 
applicable to the development of foetal overgrowth. What this 
research does show is that IL-6 leads to increased SNAT 2 activity, 
and as increased levels of IL-6 are associated with obese pregnancy 
and have been correlated to increased foetal adiposity, this 
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identifies a molecular link how the inflammatory status of the obese 
mother may potentiate foetal overgrowth74.  
Although maternal obesity is not associated with increased maternal 
circulating TNF-α levels, placentae of obese women have been 
demonstrated to contain macrophages with increased gene expression 
for TNF-α, IL-6 and IL-190. 
1.1.8.5. Increased Macrophage Numbers Are Found in the Placentae of 
Obese Women: 
As mentioned previously, obesity is associated with excess of 
accumulation of macrophages within WAT, and it appears that 
macrophages also accumulate within the placenta of obese women. 
Challier et al, functionally and phenotypically characterised the 
placentae of twenty obese and fifteen lean women90. Placentae of 
obese women were reported as containing twice as many macrophages as 
placentae of lean women, and that these macrophages were activated 
with increased gene expression for pro-inflammatory cytokines. Some 
macrophages (CD14+) also demonstrated increased gene expression 
encoding for MCP-190. 
Studies in support of this finding have been conducted in obese 
baboons, which also reported increased numbers of intra-villous 
macrophages present within the placenta, however they did not 
speculate as to their origin91. Challier et al speculated that the 
activated monocytes present within the obese mother’s circulation 
contributed to the accumulation of macrophages present in the 
placenta, and that the macrophages were recruited by increased 
placental expression of MCP-190. The reason for the initial increase 
of MCP-1 gene expression was unknown. Elevated levels of IL-6 and 
CRP were also demonstrated in the obese women, with, again, no 
difference in TNF-α concentration. In addition, when umbilical blood 
was assessed, there was no reported increase in gene expression for 
pro-inflammatory cytokines in mononuclear cells, implying these 
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foetal macrophages were not activated. From these findings it was 
assumed that the pro-inflammatory status of the obese mother was 
confined to the mother and placenta, and not directly conveyed to 
the foetus90. 
There was no definite reason found for the increased numbers of 
macrophages within the placentae of obese women, but it could be 
speculated that their recruitment occurs via the same mechanism as 
macrophage recruitment occurs in adipose tissue in obesity. Their 
presence, however, raises the possibility that the activated 
macrophages, found in the placentae of obese women, may be involved 
in the regulation of placental nutrient transporters, such as sPLA2 
and system A, resulting in altered foetal growth and development. 
Future research into this topic to elucidate the initial recruitment 
stimulus and true functional role of macrophages in the placentae of 
obese women is needed. 
Research has also been conducted into how alterations in cytokines, 
leptin and insulin may affect overall placental structure and how 
this may affect foetal growth. Radaelli et al profiled the 
expression of genes altered in the placenta in response to the 
diabetic insult92. A total of 110 genes were shown to be modified in 
response to GDM, with a third of the genes regulating inflammatory 
responses and endothelial reorganisation. The authors’ hypothesised 
that the inflammatory environment present in GDM had induced the 
recruitment of TNF-α, IL-1, and leptin receptors to the MVM of the 
syncytiotrophoblast, which were then activated by the inflammatory 
mediators, present within the maternal circulation92. This then led 
to the activation of multiple genes and transcription factors, 
mainly involved in the regulation of placental structure. For 
example, TNF-α, IL-1, and leptin receptor activation were shown to 
induce genes encoding for fibronectin and matrix metalloproteinases 
(MMPs)92. MMPs have been shown to degrade extracellular matrix (ECM) 
proteins resulting in alterations in the cellular network and 
  
33 
 
release of growth factors in the placenta, culminating in increased 
angiogenesis and disturbed placental structure92.  
 
Figure 1-6 - Diagram illustrating the molecular interactions occurring in the 
syncytiotrophoblast in response to the inflammatory environment characteristic of 
GDM
92
.
 
This diagram demonstrates how the inflammatory status of the 
diabetic mother may lead to dysregulation of placental structure. 
Potentially this dysregulation could alter the function of the 
placenta and the nutrient supply to the foetus, and ultimately 
foetal growth. How, or even if, this actually occurs is, however, 
unknown. 
 
A recent study, more applicable to the situation of obesity, 
examined the effect of mild hyperglycaemia on placental structure 
and function. Pietro et al reported that placentae from women with 
mild hyperglycaemia were shown to contain more terminal villi than 
placentae from women with NGT, GDM, or clinical diabetes mellitus93. 
This was deemed as a response to hyperglycaemic induced hypoxia. 
Hyperglycaemia is known to cause increased glycosylation of 
haemogloblin, causing alterations in its structure, and impairing 
oxygen transport. Therefore, by increasing the number of terminal 
villi, a larger surface area for materno-foetal gas exchange is 
provided, overcoming the induced hypoxia93. It was then speculated 
that this would also lead to increased surface area for nutrient 
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exchange, possibly providing a link between maternal hyperglycaemia 
and foetal macrosomia93. 
 
As obesity is also associated with transient episodes of 
hyperglycaemia, and elevated levels of pro-inflammatory cytokines, 
it could be postulated that similar mechanisms may also apply to 
placentae of obese women, leading to altered placental structure and 
foetal growth. However, although thorough searches have been 
conducted, there appear to be no studies documenting placental 
changes in obese women who deliver live, AGA, or macrosomic, 
neonates. Therefore, without knowing what structural changes are 
associated with obesity it is impossible to speculate what may be 
occurring within the placenta or how this may influence foetal 
growth. 
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1.1.9. Summary: 
In summary, obesity is associated with multiple metabolic changes 
and when this is combined with the inflammatory status of pregnancy, 
further metabolic alterations are instigated. Obese mothers are 
known to produce SGA neonates and macrosomic neonates, both of which 
are at increased risk of developing metabolic syndrome in later 
life. The mechanisms for the development of either one of these 
outcomes is unclear, or why they are predisposed to metabolic 
syndrome. 
 
With regard to the development of macrosomia, several factors have 
been implicated: 
 
- Hyperinsulinaemia and decreased insulin sensitivity leading to 
transient episodes of hyperglycaemia and increased placental 
glucose transport, 
- Hyperleptinaemia which has been shown to affect placental size 
and the development of appetite regulation within the foetus, 
- Increased numbers of activated macrophages within their 
placentae whose function is unknown, 
- Elevated levels of circulating IL-6 which have the potential 
to increase amino acid transport via system A. 
 
See Figure 1.7 overleaf for schematic diagram of possible theories 
implicating maternal obesity in the development of foetal 
macrosomia.
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Figure 1.7: Schematic diagram summarising the possible theories implicating maternal obesity in the development of foetal 
macrosomia. 
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However, much of this is hypothetical and based on animal models, 
with no definitive answers coming from human studies. Very few of 
the regulatory factors and the intra- and extracellular mechanisms 
in foetal overgrowth are known. With so much that is unknown about 
the cellular interactions relating to obesity alone, it is nigh on 
impossible to unravel the multitude of interactions occurring in 
obese pregnancy, and the potential implications these may have to 
mother and foetus.  
 
Obesity, however, is rising in adults, and in 2009 approximately 33% 
of pregnant women were overweight and 23% were obese in the UK 
alone94. The WHO speculates that by 2015 in the UK, 73% of women aged 
thirty or over will be overweight.95 This will mean that more and 
more foetuses will be exposed to a detrimental in utero environment, 
putting them at increased risk of becoming obese themselves. It is 
therefore pertinent that these interactions are unveiled in an 
attempt to break the perpetuating cycle of obesity-inducing obesity 
in subsequent generations. If no efforts are made to break this 
cycle then we are simply condemning future generations to a short-
lived life of obesity. 
 
This study, by no means, aims to address all of the mechanisms 
related to the development of foetal macrosomia in relation to 
obesity. What it does seek to explore are the following factors: 
 
- The relationship of maternal variables, especially BMI, and 
neonatal birth weight and adiposity. It is hypothesised that, 
in agreement with previous studies, that an increase in birth 
weight will be seen in neonates of obese mothers which will 
correlate to maternal pre-gravid BMI. 
- The morphology of placentae of obese women. It has yet to be 
discovered whether the placentae of obese women, who do not 
suffer from GDM, have any associated placental morphological 
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changes on histological examination. The null hypothesis is 
that there will be no morphological changes detected on light 
microscopy in the obese participants’ placentae when compared 
to lean participants’ placentae. Placental morphology will 
then be examined in relation to foetal adiposity and any 
correlations noted. 
- Determine whether glucose, leptin, TNF-α, or insulin have any 
regulatory effect on the production and/or secretion of 
placental cytokines from placentae of lean and obese women 
which are cultured in vitro. It is hoped that the results will 
help elucidate the placental regulation of cytokine 
production. The null hypothesis is that lean and obese 
placentae produce the same quantities of pro-inflammatory 
cytokines. 
 
In accordance with this, the aims of the study as illustrated in 
Figure 1.7 are: 
 
1. To describe the association between maternal demographics and 
neonatal anthropometry, 
2. To compare the patterns of placental morphology between lean 
and obese pregnant women and its association with neonatal 
anthropometry, 
3. To compare basal, and stimulated, production, and secretion, 
of pro-inflammatory cytokines between lean and obese pregnant 
women. 
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 Figure 1-8 - Diagram summarising the aims of the study.
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Chapter 2: Materials and Methods: 
2.1. The ‘Fit for Birth’ Study: 
Participants were recruited as part of the ‘Fit for Birth’ (FFB) 
study; a two year prospective study, based at the Liverpool Women’s 
hospital, investigating obese, pregnant women. The ‘Fit for birth’ 
study has two overall aims: 
1. ‘To determine the scale of the problem of obesity in 
pregnancy, in the Liverpool PCT area.’ 
2. ‘To generate information that can be used to develop 
services and plan further research.’ 
 
By gathering this information the study hopes to improve the care, 
and obstetric outcomes, of obese women in Liverpool during 
pregnancy. It also hopes to reduce the long-term risks of poor 
health in obese women, and their families. 
 
Recruitment of participants was conducted over a one year period, 
from June 2009 to June 2010, and was based on the body mass index 
(BMI) of women during their first booking appointment with their 
midwife. Dependent on their booking BMI, participants were eligible 
for one of three subgroups: 
Booking BMI 
Section of study participant 
is eligible for 
What participation involves 
Less than 30 
Not eligible for any 
section of the study 
No participation required, 
patient just attends normal 
antenatal appointments. 
30-34.9 
Level one - ‘Fit for 
birth’ 
Attends regular midwife 
appointments and is weighed at 
each appointment. 
Greater than 35 
Level two - ‘Fit for Birth 
Plus’ 
Is invited to the Liverpool 
Women’s Hospital to attend 
specialised clinics (see below 
for further information) 
Table 2.1 - Table to show the eligibility of women from the Liverpool area with 
dependent upon BMI to the FFB study. 
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Level one of the study, simply entitled ‘Fit for Birth’, only 
required participants to be weighed at their routine antenatal 
appointments by their community or hospital midwife. Maternal and 
obstetric data was then extracted from their medical notes. This 
level aims to calculate descriptive statistics of NHS attendance 
rates, and summarise weight gain during pregnancy, of obese pregnant 
women in Liverpool. 
 
Level two of the study, ‘Fit for Birth Plus’, entails a much more 
detailed analysis of the participant. Each participant was invited 
to attend three specialist clinics at twelve, twenty-eight and 
thirty-six weeks gestation. During each appointment information was 
gathered about the participant’s diet, physical activity, health-
related quality of life, and sleep. As part of this level the 
participant was also invited to consent for histological examination 
of their placenta and neonatal anthropometric measurements of their 
baby. This level aims to generate detailed longitudinal, descriptive 
statistics to aid service delivery and, analyse the impact of 
maternal variables on obstetric and neonatal outcome. (See Appendix 
I for patient information sheet).  
 
Consent for the FFB study was performed by the woman’s midwife or by 
a member of the FFB team who was based at the booking centre. The 
candidate did not participate in the selection or consenting 
process. 
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2.1.1. Placental Histological Examination Recruitment: 
This section of the ‘Fit for Birth’ study was conducted by the 
candidate over a ten month period, from September 2009 to June 2010, 
with the kind help of the midwives on the delivery suite and 
midwifery-led unit at the Liverpool Women’s hospital. 
 
2.1.1.1. Eligible participants: 
For placental histological examination, the following inclusion 
criteria were applied to the participants: 
- Participants must have qualified and consented to the ‘Fit 
for Birth Plus’ level; 
- The gestational age at time of delivery must be greater than 
36 weeks; 
 
Exclusion criteria were: 
-  Participants under the age of eighteen (due to legal reasons 
deemed by the ethics comittee). 
 
Participants were entitled to withdraw their consent for placental 
histology and neonatal anthropometric measurement, at any time, 
without withdrawing their consent from other aspects of the ‘Fit for 
Birth Plus’ level of the study. 
 
In order to ensure participants’ placentae were sent for 
histological examination the candidate designed a form to highlight 
their participation within the study to their delivering midwife 
(Appendix II). In order that these forms were not overlooked, they 
were placed at the front of the patient’s hand-held maternity notes. 
Initially, these forms were distributed during the participant’s 
third visit to the ‘Fit for Birth’ clinic as the appropriate 
gestation for inclusion would have been reached. However, due to 
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unforeseen reasons, many participants who had consented for ‘Fit for 
Birth Plus’ at their booking appointment, were not given follow-up 
appointments at the ‘Fit for Birth’ clinic. Out of a possible one 
hundred and thirty eight participants consented to the ‘Fit for 
Birth Plus’ level of the study during the ten month period, only 
seventy nine were given appointments to the clinic. During 
investigation into this problem it evolved that there had been 
communication problems regarding whose responsibility it was to book 
participants’ appointments; the community midwife or the study 
administrator. During this time period irretrievable data was lost 
as many participants’ gestational ages were too advanced to attend 
the clinics. In an attempt to improve recruitment rates for the 
placental histology aspect of the study, the candidate sought 
ethical approval to contact the participants by post. This was 
granted in late November and from then onwards, reminders were 
distributed to all participants by post (Appendix III). 
 
Recruitment of placentae for histological examination relied heavily 
on the co-operation of the midwives who attended to the participants 
during their delivery. Therefore, much effort was made to advertise 
the study to all the midwives on delivery suite and midwifery-lead 
unit to ensure that the study was well publicised. This was achieved 
by regularly attending staff handovers and distributing posters 
detailing information about the study (Appendix IV). 
 
Participant admission to the hospital was monitored on a daily 
basis. This was done by checking the various maternity wards’ 
admission boards and the hospital computer system; ‘Meditech’. 
Depending upon whether the participant was antenatal or postnatal 
when their admission was detected, one of the following four options 
was followed: 
  
44 
 
- Antenatal - If a participant had been admitted and was yet to 
deliver, consent for placenta histology was verified, and if 
confirmed, a form was placed within their notes, if there was not 
one already there. Their midwife was then informed of their 
participation and notified of the following procedure; 
immediately after delivery the placenta was to be placed in a 
‘Fit for Birth’ histology bucket and placed in the fridge, to 
prevent decomposition, with a corresponding, completed ‘Fit for 
Birth’ histology form (Appendix IV). The individualised ‘Fit for 
Birth’ histology bucket and form were designed to highlight the 
placentae as part of the study to the Alder Hey pathologists who 
were to conduct the histological examination.   
 
- Postnatal and placenta had been sent for histological examination 
– If a participant had already delivered prior to their admission 
being detected and their midwife had already sent their placenta 
for histological examination then, irrespective of whether the 
participant had attended a ‘Fit for birth’ clinic, neonatal 
anthropometric measurements were performed. 
 
- Postnatal and placenta had not been sent for histological 
examination but participant has attended at least one ‘Fit for 
Birth’ clinic – If this was the case then neonatal anthropometric 
measurements were still performed as these could be correlated to 
other maternal information gathered during the FFB clinic 
appointment(s). 
 
- Postnatal and placenta had not been sent for histological 
examination and participant has never attended a ‘Fit for Birth’ 
clinic – although neonatal anthropometric measurements could be 
conducted there would be no maternal or placental information to 
correlate it to and, therefore, it was decided that it was futile 
to measure the neonates of these participants. Every effort was 
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made to avoid this situation through rigorous monitoring of the 
wards and advertisement to the midwives to prevent loss of vital 
data.  
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2.1.2. Neonatal Anthropometric Measurements: 
One variable of particular interest was neonatal body composition, 
especially the percentage of total body fat, which can be estimated 
in several different ways. The measurement of total body water is 
one method; however this requires the use of a mass spectroscopy 
facility, which due to funding restrictions the candidate did not 
have access to. The second method is to estimate total body 
electrical conductivity (TOBEC), which requires access to specialist 
equipment, which again, the candidate did not have access to.96 The 
third method is to calculate the fat mass of the neonate using a 
statistical model. The first group of researchers to propose a 
statistical model for estimating neonatal fat mass was Dauncey et al 
in 1977. It was based on the following assumptions: 
 
- The head is a sphere devoid of fat; 
- The trunk is a cylinder covered by a layer of subcutaneous 
fat whose circumference is equal to the chest circumference, 
and whose length is equal to the crown-rump length minus the 
diameter of the head;  
- The upper limbs are cylinders covered by subcutaneous fat 
whose circumference equals the circumference of the upper 
arm, and whose length equals the length of the upper and 
lower arm;  
- The lower limbs are cylinders covered by subcutaneous fat 
whose circumference equals the mean of the mid-thigh and 
calf circumferences, and whose length equals the length of 
the upper and lower leg.  
 
In order to calculate the overall volume of the subcutaneous fat, 
first the depth of the subcutaneous fat covering each of the 
cylinders needs to be known. This can be estimated by measuring the 
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overlying skin fold of each ‘cylinder’ using callipers. The volume 
of each cylinder is then calculated by: 
 
- length x circumference x depth of subcutaneous fat 
 
Total body fat can then be estimated by summing all the volumes of 
fat covering the cylinders and multiplying by 0.9, the density of 
fat.97 
 
This model remained unchanged until 1995 when Catalano et al 
redefined this equation. Fat mass was estimated on one hundred and 
ninety four neonates using TOBEC and the anthropometric statistical 
model. From their research, Catalano et al derived that the 
following statistical model had better correlation with estimated 
neonatal fat mass than the previously proposed statistical model by 
Dauncey et al: 
 
‘(0.39055*birthweight(kg))+(0.0453*Flank skinfold thickness(mm))-
(0.03237*length(cm))+0.54657’ 
 
 
Figure 2-1 - Graphs taken from Catalano et al's paper entitled ‘Anthropometric 
estimation of Neonatal body composition’. The graphs illustrate the correlation of 
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TOBEC estimated neonatal fat mass with: a) Neonatal fat mass calculated from the 
model devised by Catalano et al, and b) Neonatal fat mass calculated by the model 
devised by Dauncey et al
96
. 
As can be seen from the graphs Catalano et al’s statistical model 
had an R2 = 0.84 when compared to TOBEC fat mass estimation, whereas 
Dauncey et al’s only had an R2 = 0.5410. Based on these results, it 
was decided that the statistical model proposed by Catalano et al 
would be used in the study to estimate neonatal fat mass, as TOBEC 
could not be performed due to financial constraints. 
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Therefore, in view of calculating neonatal fat mass and free-fat 
mass, the following anthropometric measurements were performed: 
 
- Length – the length of the neonate was measured to the nearest 
millimetre using a one metre, portable roll mat. The neonate was 
laid supine with their head and feet exposed. The participant, or 
the participant’s partner, was asked to hold the neonate’s head 
against the head board while the candidate straightened the 
neonate’s legs whilst moving the adjustable foot board towards 
the feet. The reading was taken once the legs were straight and 
the feet were pressed flat against the foot board. On three 
occasions, the roll mat had to be placed inside the neonate’s cot 
as there was no other available space for the roll mat to be 
placed on. The reading was, therefore, much more difficult to 
perform and due to the manner in which the roll mat had to be 
placed gave a greater than actual reading.  
 
- Flank skin fold thickness – this was measured to the nearest 0.2 
of a millimetre in the mid-axillary line just above the superior 
iliac crest using Harpenden callipers. The skin-fold was held 
using the thumb and index finger, ensuring no underlying tissue 
was included, and the callipers applied for approximately two 
seconds until the needle steadied (see Appendix VI for reference 
of method). The measurement was performed twice, however if the 
second measurement was greater or less than ten percent of the 
first measurement then the measurement was performed for a third 
time. An average of the two, or three, measurements was then 
taken. All measurements were performed on the right hand side of 
the neonate. 
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- Head circumference – the occipital frontal circumference was 
measured in centimetres using a disposable, paper tape measure. 
This measurement was performed once. 
 
These measurements were only performed by the candidate once it had 
been verified that a participant had either; 
 
- Had their placenta sent for histological examination irrespective 
of attending a ‘Fit for Birth’ clinic, or; 
- Had not had their placenta sent for histological examination but 
had attended a ‘Fit for Birth’ clinic. 
 
Before visiting the participant on the ward, the candidate first 
ensured that the participant had been deemed healthy to receive 
visitors by their midwife. Once confirmed, the participant’s consent 
for neonatal anthropometric measurements was checked. Five 
participants chose to withdraw their consent at this point, as they 
deemed it detrimental to the care of their baby. If, however, 
consent was reconfirmed then the anthropometric measurements listed 
above were performed. 
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Table 2.2 - Table to summaries numbers of placentae obtained and neonatal 
anthropometric measurements performed. 
 
Reasons for not obtaining 
placenta for histological 
examination 
Reasons for not obtaining neonatal 
anthropometric measurements 
Number of 
placentae 
sent 
for histological 
examination 
 
74 
49 
 
Participant
s had 
attended at 
least one 
‘Fit for 
birth’ 
clinic 
N/A 
25 
Neonatal anthropometric measurements 
performed 
2 
Participant was repeatedly unavailable 
and was discharged prior to 
measurements being obtained 
1 
Premature baby – placenta should not 
have been sent – neonate too critically 
ill to be handled by candidate 
1 
Intra-uterine death therefore neonate 
not measured 
1 Homebirth 
12 
Candidate was not contacted by the 
attending midwife 
7 
 
The candidate was unavailable to 
perform the neonatal anthropometric 
measurements 
25 
Participant
s had never 
attended a 
‘Fit for 
birth’ 
clinic 
N/A 
13 
Neonatal anthropometric measurements 
performed 
1 Participant withdrew their consent 
1 
Participants were repeatedly 
unavailable 
4 
The candidate was unavailable to 
perform the neonatal anthropometric 
measurements 
6 
The candidate was not contacted by the 
attending midwife 
Number of 
placentae 
not sent for 
histological 
examination 
62 
 
 
 
 
28 
 
 
Participant
s had 
attended at 
least one 
‘Fit for 
Birth’ 
Clinic 
3 
No reminder in notes as did 
not attend third ‘Fit for 
Birth’ clinic appointment, 
prior to ethical approval 
for contact via post. 
3 
No form in notes therefore the 
candidate could not be contacted by 
midwife and no neonatal anthropometric 
measurements were performed 
4 
Participants had not placed 
the form in their hand-held 
notes – checked by candidate 
5 
Neonatal Anthropometric measurements 
performed 
4 
Participants withdrew their 
consent 
4 Participants withdrew their consent 
3 
Participants had preterm 
deliveries 
3 
Premature babies – neonates too 
critical to be handled by the candidate 
12 
Participants’ midwives did 
not send their placenta for 
histological examination or, 
the participant had not 
placed the form in their 
notes (notes unavailable for 
candidate to check) 
11 
The candidate was not contacted by the 
attending midwife 
1 Participant moved away 1 Participant moved away 
1 Emancipated 1 emancipated 
34 
Participant
s had never 
attended a 
‘Fit for 
Birth’ 
clinic 
 
5 
Participants had preterm 
deliveries 
5 
Premature babies – neonates too 
critical to be handled by the candidate 
26 
Participants’ midwives did 
not send their placenta for 
histological examination or, 
the participant had not 
placed the form in their 
notes (notes unavailable for 
candidate to check) 
26 
No neonatal anthropometric measurements 
were performed as no other maternal or 
placental histological data to 
correlate it to 
3 
Delivered at alternative 
hospital 
3 Delivered at alternative hospital 
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2.1.3. Control Participants: 
The ‘Fit for Birth’ study postulated that, over the two year period, 
approximately one hundred and fifty placentae would be obtained from 
participants with a BMI of thirty five or greater. In order to give 
an 80% power to detect a 2.5-fold increase in the rate of maternal 
vascular underperfusion among obese participants, fifty control 
participants with a BMI of nineteen to twenty five would need to be 
recruited.   
 
During the candidate’s clinical placement, eighteen control 
participants with a BMI between nineteen and twenty five were 
recruited. The following method was used to identify and consent 
control participants: 
 
1. The theatre list for elective caesarean sections for the 
following day was obtained. 
2. All patients on the theatre list were cross-referenced with 
their BMI. 
3. Patients with a BMI between nineteen and twenty five were 
noted and located on the ward. 
4. The candidate introduced themselves, the ‘Fit for Birth’ and 
the reason for approaching the patient.  
5. Patients were given a ‘Patient Information Sheet’ and given 
time to read it (Appendix VII). 
6. The candidate then answered any questions the patient had 
with regard to participation within the study. 
7. The candidate then asked if the patient would like to 
participate in the study. It was made clear that the patient 
was eligible to decline the offer and it would affect their 
treatment during their hospital stay. 
8. If the patient agreed, three consent forms were filled in 
and signed by the patient (Appendix VIII). The candidate 
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then dated and countersigned these and placed a Liverpool 
Women’s Hospital patient identification label on them. 
9. One copy of the consent form was then placed in: the 
participant’s brown hospital medical records; the 
participant’s hand-held maternity notes; and finally one 
copy was kept and given to the study administrator. 
10. A control placental histology reminder form was then placed 
at the front of the participant’s hand-held maternity notes 
to identify their participation within the study to the 
theatre midwife. 
11. The candidate then informed the theatre administrator that 
the participant had consented and that their placenta 
required sending for histological examination. (Prior to 
consenting any controls, the candidate checked there were 
sufficient placental histology buckets available). 
12. Following delivery the placenta was collected from theatre 
in the placental bucket and with the corresponding, 
completed placental histology form the placenta was sent 
for histological analysis. 
13. The next day, neonatal anthropometric measurements were 
performed on the neonate. 
 
Only seventeen of the eighteen control participants consented 
to neonatal anthropometric measurements. One participant 
withdrew their consent as they did not want their baby ‘poked 
and prodded’.  
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2.1.4. Data collection: 
The following information was gathered from Meditech following a 
participant delivery: 
 
Maternal variable Neonatal variable 
Age Gestational age at birth (days) 
Weight (kg) Birth weight (g) 
Height (cm) Outcome of birth 
Body mass index (kg/m2) Apgar score at one minute 
Smoking status Apgar score at five minutes 
Ethnicity Level of resuscitation received 
at delivery  
Gravity Foetal problems during labour 
Parity Sex 
Onset of labour  
Mode of delivery  
Presentation of foetus  
Maternal problems during labour  
 
Table 2.3- Table to show information gathered from Meditech. 
Along with the neonatal anthropometric data, these variables were 
entered into a Microsoft Excel database. 
 
The following variables were then calculated and entered into the 
main Excel database: 
- Neonatal Fat Mass (kg): 
Using the statistical model by Catalano et al 
 
- Neonatal free fat mass (kg): 
= Birth weight(kg) – fat mass(kg) 
 
- Neonatal percent body fat (%): 
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= Fat mass(kg)/birth-weight(kg)*100 
- Birth weight centile: 
This was calculated by downloading a ‘bulk birth weight 
centile calculator’ from www.gestation.net. The following 
variables were necessary for the calculation and re-coded 
into: 
- Birth weight (kg) 
- Maternal height (cm) 
- Maternal weight (kg) 
- Parity 
- Ethnicity -  1 = European 
  2 = Indian 
  3 = Pakistani 
  4 = Bangladeshi 
  5 = African Carribean 
  6 = African 
  7 = Middle Eastern 
  8 = Far Eastern Asian 
  9 = South East Asian 
  10 = Unclassified 
- Gestational age (days) 
- Neonatal sex - 1 = male 
2 = female  
From this information the ‘bulk birth-weight centile calculator’ 
then calculated the individual birth-weight centiles for all of the 
neonates.98 (Appendix IX).  
Placental histology reports were received back approximately three 
weeks after the placenta had initially been sent for examination. 
The reports were then photocopied and read by the candidate. If any 
gross abnormality was detected in the report, the candidate reported 
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these to an appropriate consultant. The following variables were 
then inputted into the main Excel database: 
- Placental untrimmed weight (grams), 
- Placental trimmed weight (grams), 
- Centile of placental trimmed weight (placental 
weight with the membranes and umbilical cord 
removed). 
 
A consultant neonatologist, blinded to the BMI status of the 
participant, was then asked to classify the reports into the 
following four categories: 
 
0 = Normal 
1 = Maternal Vascular Underperfusion 
2 = Chorangiosis 
3  = Other Abnormality 
 
A normal placenta was defined as having no obvious abnormalities on 
light microscopy as reported by a pathologist who was also blinded 
as to the participants’ BMI cohort. The category of maternal 
vascular underperfusion (MVUP) was chosen as it is an important 
cause of foetal growth restriction, and therefore it was chosen to 
determine if there was any correlation between MVUP and SGA 
neonates. MVUP is diagnosed by the presence of the following 
abnormalities in a placenta (see Figure 2.3 below). Chorangiosis is 
defined by an increased number of capillaries in terminal villi and 
is believed to be a placental response to long term chronic hypoxia 
and its presence is a pathological feature. As obese mothers are 
known to suffer from transient periods of hyperglycaemia, which 
leads to poor oxygen transportation, chorangiosis was chosen to 
determine if placentae of obese participants were more hypoxic in 
comparison to placentae from lean participants. The category of 
‘other’ included any other reported placental morphological 
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abnormalities such as foetal thrombotic vasculopathy and 
chorioamnionitis99. Once the reports had been categorised, their 
categories were then entered onto the database. 
 
 
Figure 2-2 - Figure taken from a paper by Redline RW et al. It details the 
placental reaction patterns, nomenclature, and definitions used the diagnosis of 
MVUP
100
. 
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2.2. Placental Analysis: 
2.2.1. Summary of Placental Explant Incubation:  
By isolating placental tissue in the laboratory, information can be 
obtained that would otherwise be very difficult to elucidate in the 
complex in-vivo situation. One short-term model for studying the 
placenta in-vitro is placental explants incubation. Placental 
villous tissue is extracted from the placenta and incubated in a 
supportive medium whilst different variables are examined. The 
viability of this model has been proven for up to four hours, after 
this time period intracellular vacuoles are seen to form within the 
cells. This model provides a simple technique to ascertain the 
assortment of characteristics, such as nutrient transport, or 
sensitivity to stimuli, possessed by the human placenta101. It also 
presents a straightforward method for comparing normal placentae to 
placentae from pathophysiological conditions, such as, pre-
eclampsia, or gestational diabetes102. Based on this, it was 
therefore proposed that placental explant culturing would be a 
feasible means of investigating cytokine production and secretion 
within the placentae of obese, and lean, subjects.  
 
Five placentae from both obese and lean participants were incubated 
for three hours in Tyrode’s medium.  In order to minimise 
variability, all placentae were obtained from elective caesarean 
sections, as previous research has shown differences in the cytokine 
secretion of vaginally, and caesarean, delivered placentae84. 
Following a caesarean section, placentae were found to produce more 
IL-1β when stimulated with a range of TNF-α doses, whereas placentae 
obtained from a vaginal delivery were found to produce more IL-684. 
Based on this research, and ease of predicting delivery time, the 
decision was made to use placentae delivered by caesarean section. 
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2.2.1.1. Methodology for Villous Tissue Preparation and Explant 
Incubation: 
Due to the nature of this procedure and the necessity for speed, 
this section of the method was carried out by the candidate, with 
the help of the lab technician, Lisa Heathcote, and the research 
assistant Jo Drury. 
Placentae were transferred from the delivery theatre to the 
university class II laboratories in sealed placental buckets in 
conjunction with the University and Liverpool Women’s NHS Foundation 
Trust Safety guidelines103. 
 
Prior to the arrival of each placenta all equipment and solutions 
needed for the experiment were prepared in the laboratory (see 
appendix X for all specific protocols relating to laboratory work).  
 
Once a placenta had arrived from theatre the maternal and foetal 
aspects were photographed. This was done in order to ensure that 
there was an accurate record of the placenta that the pathologist 
could refer to if the dissection had majorly interfered with the 
overall placental structure.  
 
Three 1cm3 full thickness samples were then cut from the placenta. 
The samples were taken randomly from three different cotyledons of 
the placenta, to ensure a representative sample was taken, avoiding 
areas directly below the cord and from the periphery. The samples 
were then washed three times in primary buffering solution (PBS) to 
remove as much maternal blood as possible. 
 
The chorionic and decidual edges were removed and each sample was 
dissected into approximately 0.25 cm3 fragments. Six fragments, from 
a mixture of the three initial samples, were then placed into 
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scintillation vials containing 4ml Tyrodes’ solution. Vials were run 
in duplicate as one set was intended for enzyme-linked immunosorbent 
assays (ELISA) and the other for immunohistochemistal analysis. 
 
Each scintillation vial was then subjected to one of the following 
stimulants: leptin, insulin, glucose, and TNF-α (see table 
overleaf). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.4 – table to show concentrations of stimulants used during incubation. 
 
The fragments were then incubated in a shaking waterbath at for 
three hours at 37 C. During their incubation the fragments were 
exposed to the atmosphere to allow normal gaseous exchange. 
 
It should be noted here that during validation, two sets of vials 
for TNF-α were trialled, one set containing 4ml Tyrode’s solution 
and the second set containing 4ml Tyrode’s solution + 1 µl protease 
inhibitor cocktail (PI). Initially, it was thought that the TNF-α 
would degrade too rapidly and alter the overall cytokine 
Vial 
Number 
Stimulant concentration used during 
incubation period 
1 Control Tyrodes (5 mM glucose) 
2 15 mM glucose Tyrodes 
3 25 mM glucose Tyrodes 
4 Control Tyrodes+100 ng/ml leptin 
5 Control Tyrodes+1 ng/ml TNF-α 
6 Control Tyrodes+10 ng/ml TNF-α 
7 Control Tyrodes+30 ng/ml TNF-α 
8 Control Tyrodes+0.1 nM Insulin 
9 Control Tyrodes+1 nM Insulin 
10 Control Tyrodes+10 nM Insulin 
11 Control Tyrodes+100 nM Insulin 
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concentration. However, after several trials and subsequent 
analysis, the additional protease inhibitor was deemed unnecessary. 
 
After three hours the fragments from the first set of vials were 
removed from the stimulants and placed in 2ml of H2O. A PI was added 
at this point to prevent protein degradation of the fragments. The 
fragments were then incubated again for 18 hours at 4 C without 
exposure to the atmosphere. The supernatant that the fragments were 
initially incubated in was frozen at -80 C in aliquots to be used 
later for ELISA analysis (these aliquots were labelled as 
‘extracellular’ and were to be used to assess the concentration of 
cytokine the placental cells excreted in response to the different 
stimuli). The fragments from the second set of vials were removed 
and placed in 4% neutral buffering formalin (NBF) and left overnight 
to fix. The supernatant from these fragments was discarded.         
 
Following the second incubation period the fragments were removed 
and placed in 10ml of 0.3M NaOH, and incubated for  6 hours at 
37 C. This was to lyse the fragments in order for protein analysis 
to be conducted later. The supernatant from the fragments was then 
aliquotted and frozen at -80 C and was also intended for ELISA 
analysis (these aliquots were labelled as ‘intracellular’ and were 
to be used to assess the concentration of cytokine which remained 
within the placental cells following incubation). Following the 
third incubation period the vials were removed and stored at 4 C 
until protein analysis had been performed. 
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2.2.2. Summary of Methodology for Processing of Fixed Samples and 
Wax Embedding 
Due to time constraints on the candidate, the wax embedding was 
conducted by the candidate, Lisa Heathcote, and Jo Drury. 
The fragments which had been fixed in 4% NBF for 24 hours were 
removed and processed in the Shandon Citadel Processor. In summary 
the following process is followed: 
- 4% formalin in neutral buffer 45 
minutes 
- 60% Ethanol   1 hour 
- 70% Ethanol   1 hour 
- 90% Ethanol    1 hour 
- 100% Ethanol     1 hour 
- 100% Ethanol    1 ½ hours  
- 100% Ethanol    2 hours 
- Xylene 1   1 hour  
- Xylene 2   1 ½ hours  
- Xylene 3   2 hours  
- Wax 1   2 ½ hours  
- Wax 2   3 ½ hours 
 
Once finished, the blocks were then removed and further embedded in 
wax and stored at room temperature. These blocks are to undergo 
immunohistochemical staining and analysis at a later date by another 
MPhil candidate and were never intended to be included in this 
candidate’s thesis. 
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2.2.3. Summary of ELISA process: 
In order to assess the concentrations of the cytokines within the 
supernatant ELISAs were performed for the following cytokines: 
- Interleukin-6 
- Interleukin-1β 
- Tissue Necrosis Factor – α (TNF-α) 
 
ELISA is a method for detecting an antibody or antigen within a 
sample. There are several variants of methodology, with varying 
sensitivities. ‘Sandwich-ELISA’ was chosen as the technique to be 
used in this instance as provides the most sensitive method. 
 
In summary, ‘Sandwich’ ELISA involves the following: 
 
a. A known quantity of a specific, primary monoclonal antibody is 
applied to a plastic microtiter plate. 
b. Once the primary antibody has bound, it is removed, and then any 
non-specific binding sites are blocked using a blocking buffer. 
This ensures that the cytokines within the samples only bind to 
this primary antibody and not any other non-specific sites. 
c. The samples, containing the cytokines under investigation, are 
then incubated in the ‘coated’ plate. 
d. After a designated period of time, any unbound sample is removed 
and a polyclonal biotinylated antibody is added. This secondary 
antibody is specific to the cytokine which has bound to the 
primary antibody104. 
e.  Again after a designated period of time, any unbound secondary 
antibody is removed. A biotin-labelled detection antibody e.g. 
Streptavidin horseradish peroxidise (HRP), is then added. 
Streptavidin HRP consists of streptavidin which is covalently 
conjugated to the horseradish peroxidise enzyme (HRP). The 
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streptavidin binds to the biotin of the secondary antibody and 
the HRP enzyme converts a specific substrate105. 
f. The appropriate substrate, in this instance a ready-to-use 
solution of 3,3’,5,5’ - tetramethylbenzidine (TMB), is applied. 
In the presence of HRP, the TMB and peroxide contained in the 
substrate solution react to produce a blue by-product. The 
intensity of the blue colour is proportional to the amount of 
HRP activity, which in turn is related to the amount of cytokine 
bound to the primary antibody. 
g. A ‘stop’ solution, sulphuric acid in this case, is then added 
and changes the colour to yellow, inhibiting any further enzyme 
activity106. 
h. The optical density of each well on the microtitre plate is then 
read in a spectrophotometer and compared to a standard curve. 
The concentration of cytokine within each well is then 
generated. 
 
Figure 2-3 - Schematic diagram of the process used in 'sandwich' ELISA. 
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2.2.3.1. Methodology of ELISA analysis: 
ELISAs were performed for the above mentioned cytokines. This method 
has been written as if three plates were running simultaneously, one 
for each of the cytokines assayed. 
NB. - The diluent used throughout the run for IL-6 and IL-1β was 
PBS/1% BSA 
- The diluent used throughout the run for TNF-α was PBS/ 0.1% 
BSA 
 
Initially, the diluent for TNF-α contained 0.05% Tween 20, however 
this was omitted after several unsuccessful ELISA runs using this 
diluent. 
 
A plan detailing where the samples to be assayed were to be placed 
on the microtiter plate was prepared prior to the ELISA run. Samples 
were run in duplicate and an average of the two concentrations was 
taken. 
 
Antigen coating the plates: 
- The primary antibodies for each cytokine were prepared: 
- For each cytokine:  
55µl of capture antibody was added to 9945µl of 
appropriate diluent. 
- (Final concentrations: IL-6 = 200ng/ml, IL-1β = 100ng/ml 
and TNF-α = 4 g/ml). 
- Each plate was then coated with 100 µl per well of primary 
antibody and covered with plate sealer. 
- The plates were then incubated at room temperature overnight. 
 
The plates were then washed using wash buffer. The wells were filled 
forcefully and once the entire plate was full, the buffer was 
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decanted into the sink and the blotted vigorously. This was repeated 
3 times in total. The wells were then filled with 300 µl of blocking 
buffer and incubated for 1 hour at 37ºC in a Dynatech Varishaker 
Incubator. The samples to be assayed were then removed from the 
freezer and allowed to defrost in ice. 
A separate standard curve for each cytokine to be assayed was 
prepared: 
 IL-1β: 
The highest concentration of IL-1β on the standard curve was 
500pg/ml. All other standard curve concentrations were 
prepared by serial dilution using PBS/1% BSA. 
 
Code for 
plate plan 
Final concentration 
of IL-1β(pg/ml): 
S1 500.00 
S2 250.00 
S3 125.00 
S4 62.50 
S5 31.25 
S6 15.63 
S7 7.81 
S8 3.91 
 
Table 2.5 - Table to show standard curve for IL-1B. 
 IL-6: 
The highest concentration of IL-6 on the standard curve was 
600pg/ml. Again all other standard curve concentrations were 
prepared by serial dilution from this first concentration. 
Code for 
plate plan 
Final Concentration 
of IL-6 (pg/ml): 
S1 600 
S2 300 
S3 150 
S4 75.0 
S5 37.5 
S6 18.75 
S7 9.38 
S8 4.69 
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Table 2.6 – Table to show standard curve for IL-6. 
 TNF-α: 
The highest concentration of TNF-α on the standard curve was 
1000pg/ml.Once again, all other standard curve concentrations 
were prepared by serial dilution. 
 
 
 
 
 
 
 
Table 2.7 – Table to show standard 
curve for TNF-α. 
 
NB. Blank diluent was 
used as S0 for all cytokines. 
 
1:2 dilutions of the extracellular supernatants were prepared (150µl 
sample + 150µl diluents). This was done because when samples were 
run undiluted the generated cytokine concentration was greater than 
the highest concentration on the standard curve i.e. ‘>max’ 
 
1:4 dilutions of the intracellular supernatant were prepared (60µl 
sample + 180µl diluents). The reasoning for this was the same as for 
dilution of extracellular supernatant. 
 
NB. All the samples were vortexed thoroughly prior to use to ensure 
a representative sample was used for the ELISA. 
 
After one hour, the plates were removed from the incubator and 
washed three times with wash buffer. 100 µl of each standards, 
Code for 
plate plan 
Final Concentration 
of TNF-α (pg/ml): 
S1 1000 
S2 500 
S3 250 
S4 125 
S5 62.5 
S6 31.25 
S7 15.6 
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sample or diluent was pipetted into the plate and incubated for a 
further hour at 37ºC. 
 
The secondary antibodies were then prepared by performing a 1:180 
dilution (55µl antibody + 9945µl diluents) giving the final 
concentrations of each cytokine were as: IL-1β = 100ng/ml, IL-6 = 
200ng/ml, and TNF-α = 300ng/ml. 
 
After one hour, the plates were removed from the incubator and 
washed three times with wash buffer. 100 µl of the secondary 
antibody was then added to each well and then incubated for a 
further hour at 37ºC. 
 
A 1:200 dilution of the detection agent, Streptavidin HRP, was then 
prepared (50µl Streptavidin HRP + 9950µl diluents). After the hour, 
the plates were again removed from the incubator and washed three 
times with wash buffer. 100 µl of Streptavidin/HRP was added to each 
well and incubated for a further 30 minutes at room temperature. 
After 30 minutes, the plates were removed from the incubator and 
washed three times with wash buffer.  
 
100µl of TMB/H2O2 was added to each well. The solution was inspected 
prior to use and was discarded if it already appeared blue. The 
plates were then incubated, in the dark, at room temperature, for 6-
7 minutes, or until there was an adequate colour gradient along the 
standard curve. 50 µl of 1M H2SO4 was then added to each well to 
inhibit any further enzyme activity. 
 
The plate was then placed on the plate reader, and the optical 
density of the wells was then read between the intensities of 450nm 
and 540nm. A graph, plotting cytokine concentration against net 
absorbance, was then generated, giving a standard curve. A line of 
best fit was then applied and the concentration of the cytokine 
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being assayed within each sample was automatically generated using 
the standard curve. 
If any results were ‘>max’ i.e. the concentration of cytokine within 
that well exceeded the highest concentration on the standard curve, 
then, if possible, this result was repeated on another run. If any 
results were ‘<min’ i.e. the concentration of cytokine within that 
well fell below the lowest concentration on the standard curve, 
then, if possible, this result was repeated, undiluted, on another 
run. 
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2.2.4. Summary of Protein Concentration anaylsis for the Placental 
fragments: 
In order to quantify the results generated by the ELISAs, the 
protein concentration of each placental villous tissue fragment 
needed to be determined. If this concentration remained unknown then 
any recorded differences in cytokine concentration could be 
attributed to variations in the volume of villous tissue of the 
samples as opposed to any true physiological differences induced by 
the stimulants.  
To determine the protein concentration of the samples, Coomassie 
Plus (Bradford) Assays were performed on all samples. This procedure 
was chosen as it is a simple and cheap procedure for the 
determination of protein concentrations of multiple samples. The 
Bradford reagent contains coomassie G-250 dye, which when bound to 
protein, changes colour from reddy/brown to blue107. This results in 
a spectral shift of absorbance which can then, like in ELISAs, be 
read by a spectrophotometer. 
2.2.4.1. Methodology for the Bradford Protein Assay Run: 
The fragments which had been placed in 4ml of 0.3M NaOH and left to 
lyse were used for this section of the methodology. Samples were run 
in duplicate and an average of the two concentrations was taken. As 
there are only eleven samples per placenta, two placentae were 
assayed simultaneously. A standard curve was prepared as follows: 
Code used on 
plate plan 
Final Protein 
Concentration 
(µg/ml) 
S0 0 
S1 12.5 
S2 62.5 
S3 125.0 
S4 187.5 
S5 250.0 
Table 2.8 – table to show standard curve used for protein assays. 
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The standards were pipetted onto the plate (20µl standard+180µl PBS) 
and then the samples were added to the plate (10µl sample+190µl 
PBS). A smaller volume of sample was added, otherwise if 20µl was 
added the protein concentration generated was greater than the 
highest concentration on the standard curve i.e. ‘>max’. 50µl of 
Bradford’s dye reagent (at room temp) was then added to each well. 
The microtiter plate was then placed on the plate reader and mixed 
for 30seconds. The plate was read at an absorbance of 595nm. A 
graph, plotting protein concentration against net absorbance was 
then generated, giving a standard curve. A line of best fit was then 
applied and the concentration of protein within the samples was 
generated automatically using the standard curve.  
 
 
Figure 2-4 - A Typical standard curve for BSA 
and bovine gamma globulin (BGG) in the Pierce 
Coomassie Plus Protein Assay.
104 
 
Once the protein content of the villous tissue had been determined, 
the corresponding cytokine concentrations of the samples were 
divided giving a final cytokine concentration in pg/mg of protein. 
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Chapter 3: Results 
3.1. Maternal, Neonatal, and Placental Histological 
Results: 
Data which fell into the following categories was excluded from 
statistical analysis: 
- Deliveries before 258 days gestation, 
- Deliveries after 288 days gestation,  
- Neonatal data from women diagnosed with GDM.  
3.1.1. Maternal Demographics: 
Means and standard deviations (s.d.) were calculated for all 
variables, and then independent samples t-tests were performed to 
compare means and s.d’s between lean and obese participants. 
Differences in means were considered significant if the p value was 
less than 0.05. For all calculations, unless stated, equal variances 
were assumed. 
 
Lean, n = 17 
(mean+/-S.D) 
Obese, n = 85 
(mean+/-S.D) Mean 
Difference 
95% Confidence 
Interval P-value 
Mean S.D Mean S.D Lower Upper 
Age 
(years) 
30.82 4.84 29.35 5.95 -1.47 -4.52 1.58 0.341 
Height 
(cm) 
159.08 5.77 164.06 6.89 4.99 1.44 8.53 0.006 
Weight 
(kg) 
59.93 9.76 105.07 11.88 45.14 39.04 51.23 0.000 
BookingB
MI 
(kg/m2) 
23.58 2.93 39.00 3.54 15.42 13.60 17.24 0.000 
Weight 
Gain 
(kg) 
- - 
n = 18 
7.23 
 
4.82 
- - - - 
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Table 3.1 – Table to show means and standard deviations of maternal demographics 
of lean and obese participants. 
As per study design, obese participants had a higher booking weight, 
giving them an average booking BMI of 39.00. Obese mothers were also 
significantly taller than lean participants. Data on weight gained 
during pregnancy was only available for eighteen of the obese 
participants, and no data was available for lean participants. Obese 
participants had an average weight gain of 7.23 +/- 4.82kg. 
Due to the skewed nature of the variables; gravidity, parity and 
ethnicity; medians and interquartile ranges (IQR) were calculated 
opposed to means and s.d’s, then a Mann-Whitney U test was performed 
to compare the medians and IQRs between lean and obese participants. 
 
Lean, n=17 Obese, n=85 
P-Value 
Median 
Interquartile 
Range 
Median 
Interquartile 
Range 
Gravidity 3 1.5-3 2 2-4 0.698 
Parity 1 0.5-1.5 1 1-2 0.437 
Ethnicity 1 1-1 1 1-1 0.708 
 
Table 3.2- Table to show medians and IQRs of the gravidity, parity and ethnicity 
of lean and obese participants. 
There were no significant differences in the gravid, or parity, 
between the lean and obese participants. For ease, ethnicity was 
coded as specified in the method; the number one denotes for ‘White 
British’. 100% of participants in the lean cohort were white British 
and, 93% of participants in the obese cohort were also white 
British. Therefore, there were no significant differences between 
the ethnicities of the two cohorts with the majority of 
participants, in both cohorts, being white British.  
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3.1.2. Neonatal Demographics: 
For continuous neonatal data, independent sample t-tests were 
performed to assess a difference between infants of lean and obese 
participants.  
 
Lean,  
n = 17 
Obese,  
n = 85 Mean 
Difference 
95% Confidence 
Interval P- 
value 
Mean S.D Range Mean S.D Range Lower Upper 
Gestational 
age (days) 
(equal 
variances 
not assumed) 
272.24 3.63 265-282 275.41 7.54 259-287 3.18 0.76 5.59 0.011 
Birth weight 
(g) 
3180.71 516.25 2160-4050 3637.98 518.54 2480-5210 457.27 184.13 730.41 
 
0.001 
 
Birth weight 
Centile 
42.54 32.84 0.9-97.3 50.66 31.87 0.1-100 8.12 -8.76 25.01 0.342 
 
Table 3.3 - Table to show means and standard deviations of neonatal demographics 
of infants born to lean and obese participants. 
Infants born to obese participants had a higher birth weight than 
infants born to lean participants. Infants of obese participants 
were, on average 457.27g heavier than infants of lean participants. 
There was also a significant difference in gestational age of 
approximately 3days. There was no significant difference in the 
average birth weight centile between the two cohorts.  
In order to examine birth weight centiles more accurately, the 
centiles were subdivided into the following groups: <2nd, ≤9th, 9th-
91st, >91st and >98th. Also to examine if more neonates of obese 
participants were classified as macrosomic compared to neonates of 
lean participants, birth weight was also divided into two groups; 
birth weight <4000g and birth weight > 4000g. In order for this data 
to be analysed the data was first classified into separate sub-
groups and then independent T-tests were performed within each sub-
group.
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Variable Group 
Lean, n=17 Obese, n=85 
Mean 
Diff. 
95% 
CI 
P-
value 
 
No. in 
each 
sub-
group 
Mean S.D 
No. in 
each 
sub-
group 
Mean S.D 
Lower Upper 
Birth 
weight 
Centile 
0-2nd 
centile 
1 0.90 - 2 0.85 1.06 -0.05 -16.56 16.46 0.976 
2nd-
9.00th 
centile 
3 5.50 2.36 8 5.09 2.51 -0.41 
-4.21 
3.39 
0.811 
9.01th-
90.99st 
centile 
11 46.80 23.63 65 50.83 25.95 4.03 -12.63 20.63 0.631 
91st-
97.99th 
centile 
2 95.50 2.55 7 94.40 1.96 -1.10 -4.99 2.79 0.525 
98th-
100th 
centile 
0 - - 3 99.67 0.58 - - - - 
Birth 
weight 
<4000g 16 3126.38 362.92 64 3416.2 486.4 289.8 73.69 505.80 0.009 
>4000g 1 4050.00 - 21 4314.1 264.4 277.4 
264.1 
-328.1 
0.363 
 
Table 3.4 - Table to show distribution of birth weight centiles and neonatal 
macrosomia in subdivided groups of lean and obese participants. 
There was no significant difference between the lean and obese 
cohort for any of birth weight centile groups. There was a 
significance difference between the lean and the obese cohort for 
the number of neonates with a birth weight of <4000g (p=0.009). This 
is most probably attributable to the small numbers in the lean 
cohort.  
In order to examine whether there was a difference of neonatal sex 
between the two cohorts a Chi-squared test was performed. 
Variable Category Lean, n=17 Obese, n=85 
Chi-squared 
(χ2) 
P-value 
Neonatal 
Sex 
Male 10 48 
0.032 0.858 
Female 7 37 
 
Table 3.5 – Table to show p-value for number of male and female neonates within 
each cohort. 
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There was also no difference in the distribution of neonatal sex in 
lean and obese participants. 
The determinants of birth weight were then explored. Birth weight 
and birth weight centile were plotted on a set of graphs against 
maternal BMI for lean and obese participants. Graphs were plotted as 
scatter plots, displaying means, 95% confidence intervals, and the 
R2 value (square of the correlation coefficient). 
Figure 3.1 – Graph to show relationship between maternal booking BMI and birth 
weight in obese participants. 
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In obese participants, maternal booking BMI explained 0.042% of the 
variance in birth weight and therefore demonstrates that maternal 
BMI is not significantly correlated to birth weight. 
 
 
Figure 3.2 – Graph to show relationship between maternal booking BMI and 
birth weight in lean participants. 
 
 
In lean participants, maternal booking BMI explained 5.5% of the 
variance in birth weight and therefore also shows that maternal BMI 
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is not significantly correlated to birth weight. However, this graph 
does show there is slightly more (5.458%) correlation between the 
lean cohort and neonatal birthweight compared to the obese cohort. 
3.1.2.1. Neonatal Anthropometrics Measurements: 
Means and standard deviations were calculated for infants born to 
lean and obese participants. Independent sample t-tests were then 
performed to assess whether there was a significant difference 
between the two cohorts. 
 
Lean,  
n = 15 
Obese,  
n = 33 
Mean 
Difference 
95% Confidence 
Interval P-value 
Mean S.D Mean S.D 
Lower Upper 
Length (cm) 50.45 2.42 52.17 3.21 1.72 -0.15 3.60 0.071 
HC (cm) 34.34 1.31 35.39 1.06 1.05 0.36 1.75 0.004 
Flank SFT 
(mm) 
4.04 0.91 4.68 0.71 0.64 0.160 1.13 0.010 
Fat Mass 
(kg) 
0.30 0.15 0.48 0.17 0.19 0.09 0.29 0.001 
Free Fat 
Mass (kg) 
2.78 0.32 3.14 0.37 0.36 0.14 0.59 0.002 
% Body Fat 9.25 3.76 13.11 3.34 3.86 1.69 6.04 0.001 
 
Table 3.6 - Table to show means and standard deviations of neonatal anthropometric 
measurements of infants born to lean and obese participants 
In order to determine if there was a difference in the number of 
neonates which were classified as obese (defined by a % body fat > 
16%) a Pearson’s Chi squared test was performed. 
Variable Category Lean, n=15 Obese, n=33 Chi-squared 
(χ
2
) 
P-value 
% Body Fat <16% 93.3%(14) 81.81%(27) 1.098 0.295 
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>16% 6.66%(1) 18.18%(6) 
 
Table 3.7- Table to show p-value for number of obese neonates in lean and obese 
participants. 
All anthropometric measurements, except length, were increased in 
neonates born to obese participants compared to neonates born to 
lean participants. On average, neonates of obese participants had a 
head circumference which was 1.05cm bigger, and a flank skin fold 
which was 0.64 mm thicker, than neonates of lean participants. 
Overall, fat mass was increased by 190g and fat free mass was 
increased by 360g in neonates of obese participants, which 
culminated in an increased percentage by fat 3.86%. There was no 
difference in the number of neonates classified as obese in either 
cohort.  
The determinants of % body fat were then explored and plotted on a 
graph against maternal BMI for lean and obese participants. Graphs 
were plotted as scatter plots, displaying means, 95% confidence 
intervals, and the R2 value (square of the correlation coefficient). 
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Figure 3.3 – Graph to show relationship between maternal booking BMI and neonatal 
% body fat in obese participants. 
 
In obese 
participants, 
maternal booking 
BMI explained 
0.2% of the 
variance in 
neonatal % body 
fat. Therefore 
this graph 
demonstrates 
that maternal 
BMI is not 
strongly 
correlated to 
neonatal % body 
fat in the obese 
cohort 
Figure 3.4 – Graph to show relationship between maternal booking BMI and Noenatal 
% body fat in lean participants. 
In lean participants, 
maternal booking BMI 
explained 0.068% of 
the variance in 
neonatal % body fat. 
This graph therefore 
demonstrates a similar 
finding to figure 3.3, 
illustrating that 
maternal BMI in the 
lean cohort is also 
not strongly 
correlated to neonatal 
% body fat. 
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The relationship between neonatal % body fat and birth weight 
centile was then explored to determine what proportion of the 
variation in birth weight centile was attributable to variation in 
body fat. 
Figure 3.5 – Graph to show the relationship between % body fat and Birth weight 
centile in obese participants.  
 
In obese participants, % body fat explained 41.3% of the variation 
in birth weight centile. This graph therefore demonstrates that 
41.3% of the variation in birth weight centiles in the neonates from 
the obese cohort was attributable to changes in % body fat. 
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Figure 3.6 – Graph to show the relationship between % body fat and Birth weight 
centile in lean participants. 
 
 
In lean participants, % body fat explained 56.3% of the variation in 
birth weight centile. This graph therefore demonstrates that a 
greater proportion of the variation in birth weight centiles in the 
neonates in the lean cohort was attributable to % body fat compared 
to neonates in the obese cohort.  
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3.1.3. Placental Demographics: 
Four histological reports for lean participants and seven reports 
for obese participants were still outstanding; therefore these were 
excluded from analysis. 
 
Lean,  
n= 14 
Obese,  
n = 50 Mean 
Difference 
95% 
Confidence 
Interval 
P-value 
Mean S.D Mean S.D 
Lower Upper 
Placental 
weight (g) 
568.15 79.99 670.51 124.44 102.36 27.49 177.23 0.008 
Placental 
trimmed 
weight (g) 
Equal Variances 
not assumed 
474.50 59.44 546.20 119.18 71.70 25.02 118.38 0.003 
 
Obese participants had an increased untrimmed and trimmed placental 
weight in comparison to lean participants’ placentae. Maternal 
booking BMI was then plotted against placental trimmed weight for 
lean and obese participants to determine if there was any 
correlation between the two variables. 
 
Figure 3.7 – Graph to 
show the relationship 
between maternal booking 
BMI and placental trimmed 
weight in obese 
participants. 
In obese 
participants, 
maternal booking BMI 
explained 1% of the 
variation in 
placental trimmed 
weight. Therefore 
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this demonstrates that there is no significant correlation between 
maternal BMI and placental trimmed weight in the obese cohort. 
Figure 3.8 – Graph to show the relationship between maternal booking BMI and 
placental trimmed weight in lean participants. 
In lean participants, maternal BMI explained 9.1% of the variation 
in placental trimmed weight. This graph therefore demonstrates that 
in the lean cohort maternal BMI correlated more strongly (9.1% vs 
1%) with placental trimmed weight when compared to the obese cohort. 
Histological classification was then explored next. One report for 
an obese placenta was still waiting to be classified; therefore it 
was excluded from analysis. 
 
Lean, n =14 
Obese, 
 n =49 
Chi-
squared 
Value 
(χ2) 
P 
Value Actual 
Number 
% of 
total 
Actual 
Number 
% of 
total 
Histological 
classification 
Normal 3 21.43 11 22.45 
6.828 0.078 
Chorangiosis 10 71.43 18 36.73 
MVUP 1 7.14 12 24.49 
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Other 0 0.00 8 16.33 
Table 3.5 - Categorisation of patho-histological reports in lean and obese 
participants. 
A significant difference between histological reports for lean and 
obese placentae was not found when birth weight was not categorised. 
There were similar percentages of reported normal placentae in lean 
and obese participants. However, 71.43% of lean placentae had 
reported chorangiosis compared to 36.73% of obese placentae, and 
7.14% of lean placentae vs 24.49% of obese placentae had reported 
maternal vascular underperfusion. No lean placentae were reported as 
‘other’, compared to 16.33% of obese placentae which were reported 
as ‘other’. 
 
In order to determine whether any of the histological categories 
related to the development of birth weight, neonates were subdivided 
into groups dependent upon their birth weight centile in both 
cohorts. A Pearson’s Chi squared test was then performed for 
neonates of lean and obese participants. 
 
Histological Category 
Chi-
squared 
Value 
(χ
2
) 
P-value Normal MVUP Chorangiosis Other 
No. % No. % No. % No. % 
Birth 
weight 
Centile 
0-2
nd 
centile 
0 0% 1 2% 1 2% 0 0% 
8.072 0.779 
2
nd
-9
th
 
centile 
2 4% 1 2% 0 0% 0 0% 
9.01
th
-
90.99
st
 
centile 
7 14% 8 16% 14 24% 7 14% 
91
st
-97.99
th
 
centile 
2 4% 1 2% 2 4% 1 2% 
98
th
-100
th
 
centile 
0 0 1 2% 1 2% 0 0% 
 
 
Table 3.6 - Table to show association between histological categories and birth 
weight centiles in obese participants. 
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Histological Category 
Chi-
squared 
Value 
(χ
2
) 
P-value Normal MVUP Chorangiosis Other 
No. % No % No. % No. % 
Birth 
weight 
Centile 
0-2
nd 
centile 0 0 0 0 1 7% 0 
0 
3.111 0.795 
2
nd
-9
th
 
centile 
0 0 0 0 3 21% 0 
0 
9.01
th
-90.99
st
 
centile 
3 21% 1 7% 5 36% 0 
0 
91
st
-97.99
th
 
centile 
0 0 0 0 1 7% 0 
0 
98
th
-100
th
 
centile 
0 0 0 0 0 0 0 
0 
 
Table 3.7 - Table to show association between histological categories and birth 
weight centiles in lean participants. 
Placental histological category had no significant effect on birth 
weight centiles in either neonates of obese, or lean, participants. 
3.1.4. Univariate analysis 
Associations between maternal and neonatal variables were explored 
next. Depending on the type of data (continuous or categorical) 
different statistical tests were performed. 
Bivariate Pearson correlations were performed for the following 
continuous variables; maternal BMI, maternal weight gain and 
gestational age; and; birth weight, head circumference, length, 
flank skin fold thickness, % body fat and placental trimmed weight.
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Birth Weight 
(g) 
 
Neonatal 
Head 
Circumference 
(cm) 
 
Neonatal 
Length 
(cm) 
 
Neonatal 
Flank 
Skinfold 
Thickness 
(mm) 
Neonatal 
% Body 
Fat 
 
Placental 
trimmed 
weight (g) 
 
n=85 n=33 n=33 n=33 n=33 n=50 
Maternal 
BMI 
P-value 0.851 0.782 1.000 0.517 0.790 0.481 
Pearson’s 
Correlation 
Coefficient 
-0.021 -0.05 0.000 0.117 -0.48 0.102 
Parity 
P-value 0.795 0.445 0.823 0.480 0.605 0.419 
Pearson’s 
Correlation 
Coefficient 
0.029 -0.138 0.04 -0.127 
 
0.093 
 
0.117 
Gestational 
Age (days) 
P-value 0.025 0.063 0.105 0.465 0.633 0.639 
Pearson’s 
Correlation 
Coefficient 
0.243 0.327 0.287 0.132 0.086 -0.068 
Maternal 
Weight Gain 
(kg) 
P-value 
n=20 
0.228 
n=20 
0.809 
n=20 
0.789 
n=20 
0.500 
n=20 
0.227 
n=18 
0.421 
Pearson’s 
Correlation 
Coefficient 
-0.282 -0.058 -0.064 -0.160 -0.283 -0.202 
 
Table 3.8 - Table to show p-value when bivariate analysis was performed between the listed variables in the obese cohort. 
In obese participants, the only variables which significantly correlated to one another were gestational 
age and birth weight. 
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Birth 
Weight (g) 
Neonatal 
Head 
Circumference 
(cm) 
Neonatal 
Length 
(cm) 
Neonatal 
Flank 
Skinfold 
Thickness 
(mm) 
Neonatal 
% Body Fat 
 
Placental 
trimmed 
weight (g) 
 
Lean 
n=17 
Lean 
n=15 
Lean 
n=15 
Lean 
n=15 
Lean 
n=15 
Lean 
n=14 
Maternal 
BMI 
P-value 0.366 0.082 0.870 0.932 0.926 0.296 
Pearson’s 
Correlatio
n 
0.234 -0.463 -0.046 -0.024 -0.026 0.301 
Parity 
P-value 0.471 0.700 0.666 0.248 0.810 0.346 
Pearson’s 
Correlatio
n 
0.188 0.109 0.122 0.318 0.068 -0.272 
Gestational 
Age (days) 
P-value 0.04 0.012 0.01 0.725 0.192 0.759 
Pearson’s 
Correlatio
n 
0.502 0.630 0.643 0.099 0.356 -0.09 
 
Table 3.9 - Table to show p-value when bivariate analysis was performed between the listed variables in the lean cohort. 
In lean participants, gestational age correlated to birth weight, head circumference, and length. 
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A Mann-Whitney U test was performed between the following continuous 
variables; birth weight, head circumference, length, flank skin fold 
thickness, % body fat and placental trimmed weight; and the 
following categorical variable; neonatal sex.  
 
Birth 
Weight (g) 
 
Neonatal 
Head 
Circumference 
(cm) 
 
Neonatal 
Length 
(cm) 
 
Neonatal 
Flank 
Skinfold 
Thickness 
(mm) 
Neonatal % 
Body Fat 
 
Placental 
trimmed 
weight (g) 
 
Obese 
n=85 
Lean 
n=17 
Obese 
n=33 
Lean 
n=15 
Obese 
n=33 
Lean 
n=15 
Obese 
n=33 
Lean 
n=15 
Obese 
n=33 
Lean 
n=15 
Obese 
n=50 
Lean 
n=14 
Neonatal 
Sex 
0.008 0.558 0.202 0.324 0.362 0.722 0.386 0.862 0.512 0.643 0.340 0.277 
 
Table 3.10 - Table to show the p-values when Mann Whitney U tests were performed 
for the listed variables. 
In obese participants, birth weight correlated to neonatal sex. 
There were no other significant correlations with neonatal sex in 
lean or obese participants. 
A Kruskal Wallis H-test was performed between the following 
continuous variables; maternal BMI, parity, gestational age, and 
weight gain; and the categorical variable; placental histological 
classification (placental histological categories were the same as 
those listed in Table 3.6 - normal, chorangiosis, MVUP, and other). 
 
Placental 
Histological 
Classification 
Obese 
n=49 
Lean 
n=14 
Maternal BMI 1.000 0.394 
Parity 0.648 0.881 
Gestational Age 
(days) 
0.758 0.179 
Maternal Weight Gain 
n=18 
0.351 
 
 
Table 3.11 - Table to show p-values when a Kruskal-Wallis test was performed for 
the listed variables. 
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None of the maternal variables correlated significantly to placental 
histological classification in lean or obese participants. 
A Kruskal Wallis H-test was also performed between the following 
continuous variables; birth weight, head circumference, length, 
flank skin fold thickness, % body fat and placental trimmed weight; 
and the categorical variable; maternal smoking status (smoker, non-
smoker, ex-smoker). 
The smoking status of one obese participant was unknown and 
therefore was excluded from analysis. 
 
Birth Weight 
(g) 
 
Neonatal Head 
Circumference 
(cm) 
 
Neonatal 
Length 
(cm) 
 
Neonatal 
Flank 
Skinfold 
Thickness 
(mm) 
Neonatal % 
Body Fat 
 
Placental 
trimmed 
weight (g) 
 
Obese 
n=84 
Lean 
n=17 
Obese 
n=32 
Lean 
n=15 
Obese 
n=32 
Lean 
n=15 
Obese 
n=32 
Lean 
n=15 
Obese 
n=32 
Lean 
n=15 
Obese 
n=49 
Lean 
n=14 
Maternal 
Smoking 
Status 
0.479 0.646 0.437 0.826 0.331 0.211 0.271 
0.69
9 
0.686 0.458 0.481 0.322 
 
Table 3.12 - Table to show the p-values when a Kruskal-Wallis test was performed 
for the listed variables. 
Maternal smoking status did not significantly correlate to any of 
the continuous variables in lean or obese participants. 
Pearson’s Chi-squared tests were performed for the following 
categorical variables; placental histological classification, 
maternal smoking status, and neonatal sex. 
 
Placental Histological 
Classification 
Obese 
n=49 
Lean 
n=14 
Maternal Smoking Status 0.373 0.326 
Neonatal Sex 0.668 0.420 
 
Table 3.13 - Table to show p-values when a Pearson's Chi-squared test was 
performed between the following variables 
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Placental histological classification did not correlate to either 
maternal smoking status, or neonatal sex, in lean or obese 
participants. 
3.1.5. Multivariate analysis: 
Due to so many insignificant results when univariate analysis was 
performed, no multivariate analysis was performed.
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3.2. Placental Tissue Fragment Incubation Results: 
3.2.1. Demographic variables of Placentae used in Placental Tissue 
Fragment Incubation: 
Means and standard deviations (s.d.) were calculated for the 
variables, and then independent samples t-tests were performed to 
compare means and s.d’s between lean and obese participants. 
Differences in means were considered significant if the p value was 
less than 0.05. For all calculations, unless stated, equal variances 
were assumed. 
 
Obese 
n=5 
Lean 
n=5 
Mean 
Difference 
95 % 
Confidence 
Interval 
P-
Value 
Mean S.D Mean S.D Lower Upper 
Age (yrs) 30.20 4.15 33.40 3.91 3.20 -9.08 2.68 0.245 
Height (cm) 161.40 9.66 159.80 5.96 1.60 -10.11 13.31 0.764 
Weight(kg) 101.00 7.18 55.40 5.77 45.60 36.10 55.10 0.001 
BMI 39.17 5.94 21.72 2.87 17.45 2.95 10.65 0.001 
Gestational 
Age (days) 
276.00 6.78 270.20 6.87 5.80 4.32 -4.16 0.216 
Birth weight 
(g) 
3664.00 315.48 333.90 524.17 325.00 -305.92 955.92 0.269 
Birth Weight 
Centile 
49.52 24.91 59.72 27.90 -10.20 -48.77 28.37 0.559 
Length (cm) 54.54 2.46 51.18 2.10 3.36 0.28 6.69 0.049 
Head 
Circumference 
(cm) 
35.34 0.77 34.84 2.01 0.50 -1.72 2.72 0.618 
Flank Skin 
Fold 
Thickness 
(mm) 
4.08 0.92 5.00 0.83 -0.92 -2.19 0.35 0.135 
Fat Mass (kg) 0.396 0.067 0.420 0.161 -0.02 -0.20 0.156 0.766 
Fat Free Mass 
(kg) 
3.27 0.27 2.92 0.38 0.35 -0.14 0.84 0.135 
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% body Fat 10.81 1.48 12.27 3.00 -1.46 -4.91 1.99 0.358 
Placental 
Weight (g) 
580.50 205.77 510.00 52.89 70.5 -296.73 437.73 0.584 
 
The only significant difference between the two cohorts was maternal 
weight and BMI which was expected given the two separate cphorts. 
All participants in the two cohorts were white British, non-smokers. 
Both cohorts had an average parity of one, and a gravidity of two. 
Case summaries were performed for all cytokines measured and 
conditions used. General linear modelling was performed to examine 
the effect of; BMI, the stimulant, and BMI and the stimulant in 
combination. These statistics were performed to examine whether:  
a) There was any difference under basal conditions between lean 
and obese placental cells (‘BMI’ column); 
b) The stimulant alone had any effect on cytokine production 
(‘stimulant’ column) and finally; 
c) There was a difference in the behaviour of the lean and obese 
placental cells in response to the stimulant (‘BMI*Stimulant’ 
column). 
The terms intra- and extra-cellular have been used throughout; 
extra-cellular denotes to the quantity of cytokine secreted, and 
intra-cellular denotes to the residual amount of cytokine left 
within the cells.   
Tables are subdivided according to which cytokine was measured. 
3.2.2. Effect of Glucose, Leptin, TNF-α and Insulin on IL-1β 
Production by Lean and Obese Placental Tissue Fragments: 
 IL-1β Extracellular IL-1β Intracellular 
 BMI Stimulant  
BMI* 
Stimulant 
BMI Stimulant  
BMI* 
Stimulant 
5 mM glucose 
0.371 0.000 0.482 0.548 0.000 0.963 15mM Glucose 
25 mM glucose 
Leptin 100ng/ml 0.087 0.718 0.522 0.487 0.997 0.815 
TNF-α  1ng/ml 
0.200 0.163 0.791 0.689 0.716 0.765 
TNF-α 10ng/ml 
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TNF-α 30ng/ml 
0.1 nM Insulin 
0.007 0.986 0.668 0.508 0.785 0.741 
1 nM Insulin 
10 nM Insulin 
100 nM Insulin 
 
Table 3.14 - Table to show P-values when General linear modelling was performed 
for IL-1B concentrations 
 
Graphs, displaying standard error bars, were then made for any 
results with a p-value<0.05.  
3.2.3. Glucose stimulation: 
 
 
Figure 3.9 – Histogram to show IL-1β secretion when stimulated with increasing 
concentrations of glucose. 
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Figure 3.10 – Histogram to show intracellular IL-1β concentration when stimulated 
with increasing concentrations of glucose. 
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3.2.3.1. Insulin Stimulation: 
 
Figure 3.11 - Histogram to show extracellular IL-1β concentration when stimulated 
with increasing concentrations of insulin. 
 
Figures 3.9, and 3.10, show that lean and obese placental fragments 
behave the same way to increasing concentrations of glucose 
(p=0.482, p=0.963). Intracellular and extracellular concentrations 
of IL-1β were significantly reduced in response to increasing 
glucose concentrations in both cohorts (p=0.000).  Figure 3.11 shows 
that under basal conditions obese placental fragments secreted 
(extracellular concentration) of IL-1β under basal conditions 
(p=0.007). There was no difference in the response of lean and obese 
placental fragments to insulin stimulation. Insulin, leptin and TNF-
α did not significantly affect the intra- or extra-cellular 
concentration of IL-1β secreted from the placental cells. 
 
BMI - P = 0.007 
Stimulant – P=0.986 
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3.2.4. Effect of Glucose, Leptin, TNF-α and Insulin on IL-6 
Production by Lean and Obese Placental Tissue Fragments: 
 IL-6 Extracellular IL-6 Intracellular 
 BMI Stimulant 
BMI* 
stimulant 
BMI Stimulant  
BMI* 
condition 
5 mM glucose 
0.000 0.000 0.545 0.000 0.000 0.502 15mM Glucose 
25 mM glucose 
Leptin 100ng/ml 0.011 0.607 0.683 0.002 0.710 0.868 
TNF-α  1ng/ml 
0.138 0.031 0.968 0.000 0.006 0.981 TNF-α 10ng/ml 
TNF-α 30ng/ml 
0.1 nM Insulin 
0.010 0.524 0.644 0.002 0.847 0.934 
1 nM Insulin 
10 nM Insulin 
100 nM Insulin 
 
Table 3.15 - Table to show P-values when general linear modelling was performed 
for IL-6 concentrations 
Under basal conditions the obese placental fragments were shown to 
secrete and contain a higher residual volume of IL-6 compared to the 
lean placental fragments (denoted by the ‘BMI’ column, p=0.000).  
Increasing concentrations of glucose were shown to significantly 
reduce the amount of IL-6 secreted from the fragments and the 
residual concentration of IL-6 within the cells (denoted by the 
‘stimulant column’ p=0.000). The response of the lean and obese 
placental fragments was the same to this stimulant (denoted by no 
significant p-value in the ‘BMI*stimulant’ column. If there was a 
difference in response of the two cohorts then this p-value would be 
significant). 
TNF-α stimulation was found to have a significant effect on the 
intra- and extra-cellular concentrations of IL-6 in both lean and 
obese placental fragments (p=0.031 and p=0.006). There was no 
difference in the response from the two placental cohorts (p=0.968 
and p=0.981). 
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Neither leptin nor insulin stimulation were found to have any effect 
on the intra- or extra-cellular concentrations of IL-6 in either 
cohort (p=0.607, p=0.710, p=0.524, p=0.847). 
 
Glucose Stimulation: 
 
Figure 3.12 - Histogram to show IL-6 secretion when stimulated with increasing 
concentrations of glucose. 
 
Figure 3.13 - Histogram to show IL-6 production when stimulated with increasing 
concentrations of glucose.
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3.2.4.1. Leptin Stimulation: 
 
Figure 3.14 - Histogram to show IL-6 secretion when stimulated with 100ng/ml 
leptin. 
 
 
Figure 3.15 - Histogram to show IL-6 production when stimulated with 100ng/ml 
leptin. 
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3.2.4.2. TNF-α Stimulation: 
 
Figure 3.16 - Histogram to show IL-6 production when stimulated with increasing 
doses of TNF-α. 
 
 
Figure 3.17 - Histogram to show IL-6 production when stimulated with increasing 
doses of TNF-α. 
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3.2.4.3. Insulin Stimulation: 
 
Figure 3.18 - Histogram to show IL-6 secretion when stimulated with increasing 
doses of insulin. 
 
 
Figure 3.19 - Histogram to show IL-6 production when stimulated with increasing 
doses of insulin. 
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3.2.5. Effect of Glucose, Leptin, and Insulin on TNF-α Production by 
Lean and Obese Placental Tissue Fragments: 
 TNF-α Extracellular TNF-α Intracellular 
 BMI Stimulant  
BMI* 
Stimulant 
BMI Stimulant  
BMI* 
Stimulant 
5 mM glucose 
0.858 0.000 0.981 0.202 0.000 0.959 15mM Glucose 
25 mM glucose 
Leptin 0.562 0.577 0.465 0.295 0.802 0.919 
TNF-α  1ng/ml 
n/a n/a n/a n/a n/a n/a TNF-α 10ng/ml 
TNF-α 30ng/ml 
0.1 nM Insulin 
0.455 0.739 0.372 0.573 0.219 0.970 
1 nM Insulin 
10 nM Insulin 
100 nM Insulin 
 
Table 3.16 - Table to show P-values when General linear modelling was performed 
for TNF-a concentrations 
In keeping with IL-1β and IL-6, increasing concentrations of glucose 
were shown to have an inhibitory effect on the intra- and extra-
cellular concentration of TNF-α in both lean and obese placental 
tissue fragments (p=0.000). The response from both placental cohorts 
was the same (p=0.981, p=0.959). Leptin and insulin stimulation were 
found to have no effect on the intra- and extra-cellular 
concentrations of TNF-α in either cohort, and both cohorts were 
found to produce the same concentration of TNF-α under basal 
conditions. 
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3.2.5.1. Glucose Stimulation: 
 
Figure 3.20 - Histogram to show TNF-α secretion when stimulated with increasing 
doses of glucose. 
 
 
Figure 3.21 - Histogram to show TNF-α production when stimulated with increasing 
doses of glucose. 
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3.2.6. Dose response Calculations: 
Stimulants which were shown to have an effect on the intra- and 
extra-cellular concentrations of cytokines were then assessed to 
determine if there was a dose response relationship. General linear 
modelling was performed and the effect of each concentration was 
assessed in contrast to the effect of the preceding concentration. 
As glucose concentrations were found to affect all intra- and extra-
cellular levels of the measured cytokines, this was analysed first. 
 IL-1β 
E/C 
IL-1 β 
I/C 
IL-6 
E/C 
IL-6 
I/C 
TNF-α 
E/C 
TNF-α 
I/C 
15mM vs 5mM glucose 0.000 0.000 0.000 0.000 0.000 0.000 
25mM vs 15mM glucose 0.026 0.007 0.003 0.004 0.000 0.012 
Table 3.19 – Table to show p-values for dose response relationship of glucose on 
IL-1β, IL-6, and TNF-α production. 
Increasing concentrations of glucose were found to have an 
inhibitory effect on the intra- and extra-cellular levels of all the 
cytokines measured. 
TNF-α was also found to significantly affect intra- and extra-
cellular levels of IL-6, and therefore this was also assessed for a 
dose response relationship.  
 IL-6 E/C IL-6 I/C 
1 ng/ml TNF-α vs 0 ng/ml TNF-α 0.537 0.529 
10 ng/ml TNF-α vs 1 ng/ml TNF-α 0.043 0.002 
30 ng/ml TNF-α vs 10 ng/ml TNF-α 0.028 0.068 
Table 3.20 – Table to show p-values for dose response relationship of TNF-α on IL-
6 production. 
There was no effect on intra- or extra-cellular levels of IL-6 when 
stimulated with a 1ng/ml TNF-α compared to 0ng/ml TNF-α (control). 
When the concentration of TNF-α was increased to 10ng/ml there was a 
significant effect on both intra- and extra-cellular levels of IL-6. 
However, when the concentration of TNF-α was increased to 30ng/ml, 
there was a significant effect on extra-cellular levels of IL-6, but 
no significant effect on intra-cellular levels of IL-6. 
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Chapter 4: Discussion: 
This study has found that maternal obesity affects neonatal 
anthropometry by increasing head circumference, flank skin fold 
thickness, fat mass, free fat mass and percentage body fat. 
Histological examination revealed that although no statistically 
significant results were obtained, maternal vascular underperfusion 
appeared to be more common in the obese cohort. None of the 
placentae examined had evidence of inflammation. Incubation of 
placental tissue fragments revealed that the placentae of obese 
participants produced more IL-6 and IL-1β than lean participants, 
and that glucose had an inhibitory effect on the production of IL-6, 
IL-1β and TNF-α, which was not modified by obesity. 
4.1. Maternal and Neonatal Demographics: 
4.1.1. Maternal Demographics: 
Obese participants, by definition, had an increased booking BMI 
compared to lean participants, with an average booking BMI of 39.00 
(kg/m2) compared to 23.58 (kg/m2). Obese participants were also 
significantly taller than their lean counterparts. This should be 
taken into account as maternal height is an important determinant of 
birth weight, and therefore any observed difference in birth weight 
between the two cohorts could, in part, be attributed to difference 
in maternal height108. 
 
Average maternal weight gain in the obese participants was 7.23 +/- 
4.82 kg. This is compatible with the Institute of Medicine’s (IOM) 
2009 guidelines for recommended weight gain during pregnancy, which 
specifies that the total weight gain for a woman with a BMI>35 
should be between 5-9.09kg (11-20 pounds).109 Maternal weight gain 
was not recorded in lean participants and therefore cannot be 
commented on. 
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4.1.2. Neonatal Demographics: 
Overall, infants of obese participants had a higher birth weight 
than infants of lean participants. In addition, infants of obese 
participants also had a greater head circumference, flank skin fold 
thickness, fat mass, fat free mass, and percentage body fat. The 
rise in fat mass and fat free mass is in proportion to the overall 
raised birth weight. This study has shown that maternal pre-gravid 
obesity is associated with a rise in birth weight with, on average, 
infants of obese participants being 457.27g heavier than infants of 
lean participants.  
One possible reason for this finding may be that there was a 
significant difference in the gestational ages between the two 
cohorts. The gestational age for neonates of lean participants was 
on average 272 days, and for neonates of obese participants the 
gestational age was 275 days, giving a p-value of 0.011. Gestational 
age was then shown to significantly correlate with birth weight in 
both cohorts (lean p-value=0.04, obese p-value=0.025). Gestational 
age was also shown to significantly correlate with neonatal head 
circumference (p=0.012) and length (p=0.01) in the lean cohort. This 
discrepancy in gestational age between the two cohorts could 
therefore be the reason for the difference in birth weight seen 
between the two cohorts. Further analysis needs to be performed when 
the study numbers have increased to see if there is still a 
significant difference in gestational ages and whether this may have 
any implications for the study’s findings. 
This finding is, however, in agreement with other studies which have 
also demonstrated increased birth weight of infants born to obese 
mothers37. Surkan et al demonstrated that neonates of mothers with a 
high pre-pregnancy BMI were two to three times more likely to be 
overweight38. When statistical analysis was performed for the 
candidate’s study, to determine if more neonates of obese 
participants were; a) macrosomic, and b) obese; no statistical 
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significance was found. Whilst twenty-one neonates born to obese 
participants had a birth weight of greater than 4000g and six were 
classified as obese, compared to one macrosomic and one obese 
neonate born to a lean participant; this was not deemed 
statistically different. Thus, it can be assumed that in this study 
that birth weights of neonates of obese participants were increased 
but not sufficiently to deem them as macrosomic. 
When further statistical analysis was performed, neonatal birth 
weight was not shown to significantly correlate to maternal booking 
BMI. Maternal booking BMI accounted for 5.5% of the variance in 
birth weight in the lean participants, whereas in obese 
participants, only 0.042% of the variance was accounted for by 
maternal booking BMI (Figures 3.1 and 3.2). This is therefore in 
opposition of Szostak et al’s findings which stated that there is a 
general linear relationship between maternal BMI and neonatal birth 
weight35. From the graphs it would appear that there is, however, a 
greater association between neonatal birth weight and maternal BMI 
in the lean participants. 
A possible reason for a lack of statistical correlation between 
maternal booking BMI and birth weight may due to the fact that all 
other birth weights, irrespective of whether the infant was 
macrosomic, were included. As stated previously, obese women are 
known to deliver macrosomic, and SGA, neonates and therefore, the 
presence of the two outcomes together may mask the correlation 
maternal booking BMI has to either outcome.44 In order to determine 
more accurately whether maternal booking BMI correlates to the 
development of macrosomic, and SGA, neonates, neonatal birth weights 
should be subdivided and then analysis performed. This was unable to 
be performed due to insufficient numbers within each category, and 
therefore the lack of correlation between maternal booking BMI and 
birth weight, may be attributable to insufficient recruitment 
numbers. It does appear that macrosomia is more common in neonates 
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of obese participants but no statistical significance was found, 
which indicates that perhaps inadequate participant data was 
obtained to prove a statistical association. It will be interesting 
to see, as the study progresses over the next year, whether a 
statistical association is proven with increased participant 
numbers. 
The findings of this study are also in opposition of Catalano et al 
who also found a correlation between maternal weight at delivery and 
neonatal birth weight36. However, this may be explained by the fact 
that Catalano et al correlated neonatal birth weight to maternal 
weight at delivery, whereas this study was attempting to find a 
correlation between maternal booking BMI and birth weight. 
Therefore, the timing of when the maternal weights were taken may 
account for the lack of correlation between birth weight and 
maternal BMI in this study. However, what this does highlight the 
possibly that maternal weight gain during pregnancy may be an 
important factor governing birth weight, as this study found no 
association between maternal booking BMI and birth weight but there 
has been a proven association between maternal weight at delivery 
and birth weight. Gestational weight gain of more than 25 lb has 
previously been associated with the development of macrosomic 
neonates in morbidly obese women110. Therefore, this could be a 
potential factor mediating increased foetal growth in the obese 
cohort of participants. However, it is hard to speculate as so few 
participants within this study have data on the amount of weight 
gained during their pregnancies. The few participants where maternal 
weight gain was known would suggest that the obese participants are 
not gaining excessive amounts of weight, and that this did not 
correlate to neonatal birth weight. However, as so little data was 
known this may not be a true representation of the whole cohort, and 
therefore weight gain could still be a feasible regulatory factor 
implicated in increased foetal growth. 
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It would be interesting to relate the detailed studies on 
nutritional intake of the obese participants, which is being 
gathered as part of the FFB study, to neonatal birth weight. As 
maternal nutritional state, and substrate availability, are such 
important factors governing neonatal birth weight one would expect 
correlations between the two. In the future it would be beneficial 
to gather detailed data on weight gain, nutritional intake 
(subdivided into food groups), and birth weight, in lean and obese 
participants, and determine if there are any positive, or negative, 
correlations present. 
One positive finding of this study, which is in disagreement with 
previous studies, is that neonatal fat mass and fat free mass are 
increased in the context of obesity. Previous studies by Hull et al, 
and Sewell et al, have found that fat free mass, also known as lean 
body mass, does not tend to differ between neonates and it is mainly 
fat mass that alters30,111. In this study, neonates of obese 
participants were found, on average, to have an increased fat mass 
of 190g, and an increased fat free mass of 360g.  As neonates of 
obese participants also had a raised percentage body fat, fat mass 
must have been increased more than fat free mass was. This is in 
agreement findings of Catalano et al who also found that neonates of 
obese mothers had a raised fat mass41. The increased fat mass in 
neonates of obese participants could be attributed to factors such 
as those mentioned in the introduction, for example, maternal 
insulin resistance promoting increased glucose transport and foetal 
hyperinsulinaemia, or raised inflammatory cytokines affecting system 
A activity. However, as no information is known on the levels of 
insulin, or circulating cytokines levels, within the obese 
participants it is difficult to speculate with any real conviction 
as to why the neonates of obese participants have a raised fat mass.  
The finding that fat free mass was raised in neonates of obese 
participants may reflect specific elements of nutrition among this 
  
111 
 
population, either due to the diet among pregnant women in 
Liverpool, or, due to influences on placental nutrient handling. 
As no correlations between maternal and neonatal variables were 
found, it must, therefore, be considered that other factors, which 
were not measured in this study, are implicated in the development 
of the increased neonatal birth weight and anthropometric 
measurements in the neonates of obese participants. All that can be 
drawn from this study is neonatal percentage body fat did not 
correlate to maternal booking BMI, parity, gestational age, maternal 
weight gain, or maternal smoking status in either cohorts of 
participants. 
  
112 
 
 
4.2. Placental Demographics and Histopathology: 
Placentae of obese participants were reported as having an increased 
trimmed, and untrimmed, weight when compared to lean participants. 
Placentae from obese participants were approximately 71.70g heavier, 
once trimmed, than placentae of lean participants. However, when 
univariate analysis was performed placental trimmed weight did not 
correlate significantly to maternal BMI, parity, gestational age, 
weight gain, neonatal sex, or smoking status. 
This is in conflict with Swanson et al who reported a positive 
correlation between uncomplicated, full-term, singleton placental 
weight and maternal pre-gravid BMI. They reported that women with a 
higher pre-gravid BMI were more likely to produce heavier placentae 
and neonates78. This study has not found this correlation in this 
sample; however, it does seem feasible that an increased placental 
weight could lead to an increased surface area mediating increased 
placental nutrient transport and subsequent foetal growth. 
Stereology might be used to examine this possibility. However, in a 
study conducted by Farley et al which investigated the placental 
volumes of placentae from obese and lean baboons no differences was 
reported75. This finding, however, remains to be proven in human 
placentae. 
Again, the lack of correlation found in this study may be 
attributable to insufficient participant numbers. Placental weights 
have been shown to be increased in the obese cohort and perhaps, 
given the relatively small numbers, they do not have sufficient 
statistical power to prove an association. 
When placental histological reports were examined from the lean and 
obese participants, no significant difference was shown. Similar 
numbers of placentae were reported as normal, and as having 
chorangiosis, in both cohorts. The finding that similar numbers of 
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chorangiosis were reported in obese and lean placentae indicates 
that this finding is not exclusive to placentae of lean or obese 
participants, and that neither cohort are likely to be exposed to 
greater levels of hypoxia. Possible reasons for similarities in 
cohorts may be attributable to smoking, which was common in both 
cohorts, leading to decreased oxygen transport to the placenta and 
subsequently to the foetus. 
Although it was not statistically significant, it does appear that 
more obese placentae were reported as having MVUP. Common features 
within placentae of obese participants, classified as having MVUP, 
were increased: syncytial knotting, intervillous fibrin, nucleated 
erythrocytes, thrombosis and infarcts. It is interesting that fibrin 
was increased within placentae of obese participants, as non-
pregnant obese individuals have been demonstrated to have increased 
levels of PAI-1, a pro-coagulant factor known to lead to the 
accumulation of fibrin and atherothrombotic disease. This could be 
speculated as to the reason for increased fibrin deposition within 
the placentae of obese participants, however, further work to verify 
this are needed.  
When statistical analysis was performed to assess an association 
between different categories of birth weight centile and placental 
histological categories, no significant difference was found for 
either cohort. This finding is, however, a little confusing. This 
study has been focused on finding a link between maternal obesity 
and the development of foetal overgrowth. MVUP is a placental 
finding associated with foetal intrauterine growth restriction 
(IUGR), not foetal macrosomia and, therefore, one would expect to 
see a significant difference of placental histological category in 
different birth weight categories. This would suggest that no 
specific placental morphology is associated with the development of 
different birth weights in either cohort of participants.  
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4.3. Incubation of Placental Tissue Fragments:  
Firstly, a brief summary of the results for each cytokine measured 
is given, and then the effect of each stimulant condition is 
discussed in more detail. 
4.3.1. Intra- and extra-cellular Cytokine Concentrations: 
4.3.1.1. IL-1β: 
Increasing concentrations of glucose were shown to reduce intra- and 
extra-cellular concentrations of IL-1β. Placental explants from lean 
and obese participants responded in the same manner to the glucose 
concentrations, and there was no difference in the intra- or extra-
cellular concentrations of IL-1β in either cohort.  
When the placental explants were stimulated with increasing 
concentrations of insulin, insulin itself had no effect on the 
extra-cellular levels of IL-1β, and the response of the two groups 
was the same. However, the placental explants from the obese 
participants were shown to secrete significantly more IL-1β than the 
lean participants’ explants. 
No other stimulants had a significant effect on the intra- or extra-
cellular concentrations of IL-1β, nor was there any significant 
difference between the intra- and extra-cellular concentrations of 
IL-1β in the two cohorts. 
4.3.1.2. IL-6: 
Glucose stimulation elicited an inhibitory effect on the intra- and 
extra-cellular concentrations of IL-6 in placental explants from 
lean and obese participants. The explants from the obese 
participants were shown to produce significantly more IL-6, under 
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all glucose concentrations, than the explants from the lean 
participants. 
Intra- and extra-cellular concentrations of IL-6, in both cohorts, 
were increased by TNF-α stimulation. There was a dose response 
effect seen when the explants were stimulated with 10ng/ml and 
30ng/ml concentrations of TNF-α. Once again, the explants from the 
obese participants were shown to contain more intra-cellular IL-6 
compared to the lean participants, however extra-cellular levels did 
not differ significantly between the two groups.  
When stimulated with insulin and leptin, the presence of maternal 
obesity had no effect on IL-6, but placental explants from obese 
participants were shown to have higher intra- and extra-cellular 
concentrations of IL-6 compared to the lean participants. 
4.3.1.3. TNF-α: 
In keeping with the other two cytokines measured, intra- and extra-
cellular concentrations of TNF-α were decreased by increasing 
concentrations of glucose. Both 15mM and 25mM glucose concentrations 
had an inhibitory effect on amount of TNF-α produced by placental 
explants from lean and obese participants. 
No other stimulants were found to have a stimulatory, or inhibitory, 
effect on the production of TNF-α.  
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4.3.2. Effects of Stimulation of Cytokines Measured: 
4.3.2.1. Glucose Stimulation: 
Increasing glucose concentrations were shown to have an inhibitory 
dose response effect on the intra- and extra-cellular concentrations 
of IL-1β, IL-6, and TNF-α.  
Coughlan et al, using similar conditions to those used in this 
study, demonstrated that placentae from lean women, and women 
diagnosed with GDM, differ in response to increasing glucose 
concentrations. Cultured placental explants from lean women were 
found to decrease TNF-α production in response to raising glucose 
concentrations, whereas placental explants from women diagnosed with 
GDM were shown to increase TNF-α production.83 This is in agreement 
with Kirwan et al that stated that circulating maternal TNF-α levels 
are raised in GDM, and TNF-α is a good predictor of insulin 
insensitivity58. 
As there was no difference in the intra- or extra-cellular 
concentrations of IL-1β or TNF-α in the placental explants of the 
lean and obese participants, and glucose stimulation had an 
inhibitory effect, it appears that placentae from obese women behave 
similarly to placentae from lean women with regard to TNF-α 
production. 
Obese women are known to experience transient periods of 
hyperglycaemia. Therefore, the fact that intra- and extra-cellular 
levels are decreased by raised glucose is intriguing. One might 
speculate that the raised glucose levels may exacerbate the 
inflammatory environment within the placentae, such as occurs in 
GDM; however it appears that the opposite is true. As glucose levels 
climb, the production of the inflammatory cytokines IL-1β, IL-6, and 
TNF-α is suppressed. This suggests that raised glucose levels are 
involved in the regulation of cytokines by down-regulating cytokine 
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gene expression. Why the placentae of some obese women may do this, 
or the mechanism involved in this regulation, is unknown. It is hard 
to speculate why some obese women’s placentae appear to exhibit a 
protective response whereas other women’s placentae exacerbate the 
inflammatory situation aiding the development of GDM. 
However, a study by Lappas et al, needs to be considered. Lappas et 
al cultured placental explants for 18h from lean women, and women 
diagnosed with GDM. Glucose stimulation at 10mM, 20mM, and 40mM was 
found to increase the release of leptin in the placental explants of 
lean women but not in the explants from women with GDM112. Therefore, 
as the placental explants from the obese participants appear to 
behave similarly to explants from the lean participants under 
glucose stimulation, it could be speculated that, the increasing 
concentrations of glucose could induce increased release of leptin. 
As leptin has been linked to foetal growth, this could potentially 
represent a mechanism how maternal obesity mediates increased foetal 
growth. In order to assess whether this was true, an ELISA for 
leptin would have to be performed, which is perhaps an area for 
future research. 
Of particular importance is the finding that although cytokine 
production of IL-6 was decreased by glucose stimulation; intra- and 
extra-cellular concentrations of IL-6 levels were still raised in 
the placental explants of obese participants compared to lean 
participants. It is of particular importance as a recent study by 
Jones et al has reported a link between IL-6 and foetal adiposity in 
the placentae of obese women. System A amino acid transport 
activity, and protein expression for the system A transporter 
isoforms, were measured in cultured human primary trophoblastic 
cells, and both were found to be increased by IL-6. The isoform 
SNAT2 was found to be up-regulated in the MVMs of placentae from 
obese women who delivered LGA neonates. Thus, it was speculated that 
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the increased system A activity, secondary to IL-6 stimulation, was 
implicated in the development of increased foetal adiposity74.  
This study’s results are in conjunction with Jones et al. Raised fat 
mass has been reported in the neonates of obese participants, and 
raised IL-6 concentrations have been demonstrated within their 
placentae. Although this study has made no attempt to investigate 
the activity or expression of system A, it could be speculated that 
the raised IL-6 concentrations observed in the placentae of obese 
participants have resulted in altered system A activity and 
potentiated increased neonatal adiposity via this mechanism.  
It would be interesting to correlate the maternal circulating IL-6 
levels in the obese participants to neonatal birth weight, and fat 
mass, and determine whether these variables demonstrate any positive 
correlation. However, as maternal circulating IL-6 levels were not 
measured, this is impossible in the case of this study. This is 
perhaps an area of future research. 
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4.3.2.2. Leptin Stimulation: 
Leptin stimulation did not appear to have any effect on intra- or 
extracellular levels of any of the cytokines.  
As mentioned earlier leptin is known to be implicated in the 
development of macrosomia in the context of GDM71 and umbilical 
leptin levels have been correlated to foetal birth weight70. These 
two findings suggest that leptin is involved in the regulation of 
foetal growth; however the mechanism is currently unclear. The 
results of this study would suggest that leptin is not implicated in 
the development of foetal macrosomia, in the context of obesity, by 
affecting cytokine production within the placenta. 
One possible reason for the lack of effect of leptin on the 
production of cytokines could be leptin resistance. The 
concentration of leptin used for stimulation was 100ng/ml. In lean 
women, circulating levels at term are approximately 10-30ng/ml, and 
even in the obese women circulating levels at term are only 
approximately 30-50ng/ml58. Lepercq et al demonstrated that in obese 
placentae raised levels of circulating leptin induce down-regulation 
of leptin receptors within the syncytiotrophoblast mediating leptin 
resistance76. Thus, it could be speculated that the levels used were 
so high that they induced down regulation of the receptors, or 
completely saturated the receptors, leading to a decreased effect of 
leptin stimulation. 
Farley et al have hypothesised that the association of leptin and 
foetal macrosomia may be attributable to increased system A 
activity75. This was based on the finding that leptin has been shown 
to stimulate system A activity in the placentae of lean women72. 
However, they found that SNAT 4 expression is actually decreased in 
the placentae of obese women, and they also reported no differences 
in the expression of the system A isoforms, SNAT 1 and 2, in the 
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placentae of lean and obese women75. That work, suggests that leptin 
is involved in the regulation of system A, but due to the high 
levels of circulating maternal leptin, leptin resistance is 
instigated preventing leptin regulation of system A in the obese 
placentae. 
It is, therefore, tempting to speculate that due to leptin 
resistance, leptin does not alter the activity of system A in the 
placentae of obese women via the production of IL-1β, IL-6, or TNF-
α. However, once again as no information was gathered on the 
activity of system A this is just speculation. 
  
121 
 
 
4.3.2.3. TNF-α Stimulation: 
TNF-α stimulation affected only IL-6 production and similar effects 
were exhibited in placental explants from lean and obese 
participants. Placental explants from obese participants were 
demonstrated to contain higher intra-cellular concentrations of IL-
6.  
This is in agreement with a study by Turner et al, which 
demonstrated that TNF-α stimulation increases secretion of IL-6 in 
human placental explants over four hours incubation time. However, 
TNF-α was also found to increase IL-1β secretion, a finding this 
study did not show.80 In this study, TNF-α stimulation appeared to 
have no effect on IL-1β production in the placental explants from 
lean and obese participants. It may be speculated that IL-1β is not 
involved in the regulation of altered foetal growth. Further 
research is however needed to confirm this speculation. 
In this study, TNF-α appeared to not only increase secretion of IL-
6, but also increase overall production of IL-6 (intra-cellular 
levels+extra-cellular levels). This is in conjunction with another 
study which showed that in isolated cytotrophoblastic cells that 
TNF-α has a pronounced effect on IL-6 secretion113. 
Similar concentrations of TNF-α were used as in the study by Turner 
et al, which stated that a TNF-α concentration of >100pM 
(approximately 26ng/ml) was needed to elicit a sustained response. 
In this study, three doses of TNF-α were used 1ng/ml (~3.9pM), 
10ng/ml (39pM) and 30ng/ml (~116pM). IL-6 production was found to 
exhibit a dose response effect to 10ng/ml and 30ng/ml but not 
1ng/ml. These concentrations are significantly greater than fasting 
circulating levels found in pregnant lean women (2.13pg/ml) and 
pregnant obese women (2.80pg/ml) with normal glucose tolerance58. 
They are even greater than fasting levels found in pregnant obese 
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women with GDM, who are known to have significantly raised 
circulating levels of TNF-α. This study has shown that maternal 
obesity is associated with changes in responsiveness to TNF-α and 
thus to regulatory processes within the placenta. 
This finding could potentially explain why placentae of obese women, 
and women diagnosed with GDM differ. TNF-α is known to be 
significantly raised in GDM, but not in obese pregnancy, which may 
potentiate increased IL-6 production. As IL-6 has now been shown to 
increase system A activity this suggests a mechanism how increased 
foetal adiposity may be so closely associated with GDM. A TNF-α 
dependent effect of IL-6 on system A may be more important in GDM 
than maternal obesity without GDM. Why women with GDM initially have 
raised levels of TNF-α in comparison to obese women, is however 
unknown. 
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4.3.2.4. Insulin Stimulation: 
Insulin stimulation was not found to affect the production of any of 
the measured cytokines. This suggests that insulin is not involved 
in the regulation of placental cytokine production of IL-1β, IL-6, 
or TNF-α, and is not implicated in foetal growth through this 
mechanism. 
Previous studies conducted on placental explants cells have 
demonstrated that insulin stimulation is associated with an 
increased production of leptin, however the demographics of the 
participants involved were not given114. This could be occurring in 
the context of obesity as obese women have been shown to have 
slightly elevated circulating insulin levels in comparison to lean 
women. However, it is more likely that this is of more significance 
in the context of GDM as women with GDM are known to have 
significantly raised insulin levels58. Raised insulin levels could 
thus mediate raised leptin levels potentiating increased placental, 
or foetal, growth. However, once again this is just speculation, as 
the mechanisms of how these interactions occur are currently 
unknown. 
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4.4. Overall - Implications of Results to Overall Model of 
Obesity: 
The finding that glucose has an inhibitory effect on placental 
cytokine production in placentae from lean and obese participants is 
intriguing. Unlike the situation in GDM, which has been shown to up-
regulate genes regulated to inflammatory response, it appears that 
in the non-diabetic individual raised glucose concentrations cause 
down-regulation of cytokines, well at least IL-1β, IL-6, and TNF-α. 
Thus it can be speculated that the transient periods of 
hyperglycaemia experienced by many obese women are insufficient to 
induce foetal overgrowth by inducing increased expression of 
placental cytokines. 
Leptin stimulation was not shown to alter cytokine production in 
placentae of obese or lean participants, which could, perhaps, be 
attributed to leptin resistance. Although obese pregnancy is 
associated with raised levels of leptin compared to lean pregnancy, 
it is unsure how, or if, leptin is involved in foetal growth in the 
context of obesity. As stated earlier, leptin is known to be 
implicated in macrosomia associated with GDM; however, it is unknown 
whether this is true for macrosomia associated with obesity. From 
these results, it can be concluded that leptin is not implicated in 
foetal growth by modifying cytokine production within the placenta. 
 
TNF-α was not shown to be elevated in the placentae of obese 
participants compared to lean participants. It was thought that if 
raised levels were reported in placentae of obese participants then 
this could potentiate foetal adiposity by; a) directly increasing 
SNAT1 and 2 activity, or, b) indirectly increasing IL-6 levels 
leading to increased SNAT2 activity, or, c) increasing lipolytic 
pathways increasing the amount of PUFAs which can be used in foetal 
adipogenesis.71 However, as TNF-α levels were not elevated in 
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placentae of obese participants compared to lean participants it can 
be concluded that TNF-α in our obese cohort was not implicated in 
the development of the increased foetal adiposity. 
In contrast to this, it is interesting that TNF-α production is not 
elevated in the placentae of the lean participants. Circulating TNF-
α levels are known to be increased in non-pregnant obese women, 
however in the pregnant obese women TNF-α levels have been shown to 
be similar to that of lean pregnant women. As shown by our data, 
placental explants from lean participants did not secrete 
significantly more TNF-α than obese participants. This is consistent 
with the overall situation in pregnant obese women. This begs the 
question, why do obese women who become pregnant not continue to 
have raised TNF-α levels in comparison to lean women? It can be 
hypothesised that an inhibitory feedback loop is instigated when an 
obese woman becomes pregnant which suppresses WAT production of TNF-
α leading to the similar circulating TNF-α levels as the lean 
individual. However, it is also impossible to measure the amount of 
TNF-α that WAT produces in isolation from the placenta during 
pregnancy. Nonetheless, this is definitely an enticing area for 
future research. 
IL-6 basal production was shown to be increased in placentae of 
obese participants and production was shown to be stimulated by TNF-
α and inhibited by glucose. Therefore, in the context of obesity, 
IL-6 may be raised independently, as TNF-α levels are known to be 
not elevated, and in the context of GDM, IL-6 may be raised as a 
result of raised TNF-α levels. Thus the raised levels of IL-6 
associated with obesity puts it as a strong contender in the 
development of foetal adiposity.  
However, probably the most intriguing fact which has failed to be 
mentioned, until now, is that while placentae of obese participants 
have been shown to have elevated levels of IL-6, there is no 
evidence of inflammation on light microscopic examination. It would, 
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therefore, appear that the cytokines are not affecting the overall 
morphological appearance of the placentae. Also the speculations, 
that the placentae of obese participants may behave similarly to 
placentae of women with GDM, which were made in the introduction, 
have been shown to be false. Placentae from women with GDM have been 
shown to up-regulate TNF-α, IL-1, and leptin receptors resulting in 
altered angiogenesis and overall disruption of placental structure. 
However, there was no statistical difference between placental 
histological classification of lean and obese participants. As no 
other studies, to date, have examined the placentae of obese women 
in isolation from any other maternal morbidity, these results cannot 
be compared to other findings. 
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In summary, the study’s results show: 
 
Figure 4-1- Diagram to show summary of study's findings for the maternal, neonatal, and placental variables investigated. 
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4.5. Limitations 
4.5.1. Design of study 
There are several limitations to this study. Firstly the sample was 
not a population based sample. Sample size was determined by the 
willingness of women within the Liverpool area to consent and comply 
with the FFB study. The study was also restricted by the amount of 
resources available. Members of the team were constricted to the 
amount of hours they could input and the whole study was restricted 
by funding.  
With regard to placental explants, there are also limitations to the 
study design. A similar study, conducted by Varastehpour et al, 
demonstrated that placentae of women who delivered obese infants had 
raised TNF-α gene expression and protein content.  This current 
study differs to the study by Varastehpour et al as placentae of 
obese women were cultured, irrespective of whether the neonate was 
obese.85 As maternal obesity is associated with IUGR and macrosomia, 
on analysis the findings associated with IUGR may obscure the 
findings related to macrosomia, ultimately resulting in no 
significant findings, and thus is a limitation of this study. It 
would be advantageous to categorise neonatal adiposity prior to 
analysis to prevent one pathological mechanism masking another.  
4.5.2. Implementation of study 
For the candidate, the implementation of the study posed the biggest 
issue. There were multiple problems throughout the study, which were 
individually addressed in the most appropriate manner in order to 
solve the problems effectively.  
Primarily, the most obstructive problem to the study was participant 
consent and attendance to the FFB clinic. Consent of participants 
relied on the cooperation of the midwives, at the various antenatal 
centres, to invite eligible women to partake in the study. However, 
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due to several reasons, such as time constraints, or unawareness of 
the study, not all women that were eligible for the study were 
consented by the midwives. There was also confusion as to the 
procedure for booking appointments to the FFB clinic. Midwives 
thought it was the responsibility of the FFB administration team, 
and the administrators thought that the midwives were booking the 
appointments. As a result many women that were eligible for the 
study either were not consented, or those that were consented, were 
not given appointments to the FFB clinic. To date, fifty nine women, 
who were consented to the study, never attended a FFB clinic. 
Ultimately this led to much data being irretrievably lost. Several 
participants who had been consented but not invited to clinic 
commented on the inefficiency of the study due to lack of 
correspondence and the disappointment they had incurred as a result. 
Of the participants that were successfully consented and given an 
appointment to the FFB clinic, not all participants attended. When 
asked as to the reason why, many participants said they forgot about 
their appointment, or that the appointments lasted too long and they 
did not have the time to attend. Again, this led to loss of data. 
4.5.2.1. Problems with Obtaining Placentae and Neonatal 
anthropometric Measurements: 
During the ten month period, seventy four placentae were obtained 
out of a possible one hundred and thirty six participants consented, 
giving a success rate for obtaining placentae following deliveries 
of 54.4%. Out of the seventy four placentae obtained, thirty eight 
corresponding neonatal anthropometric measurements were obtained, 
giving a success rate of 51.4%.  As the numbers demonstrate, there 
were multiple problems experienced with regard to obtaining 
placentae and neonatal anthropometric measurements. 
The first problem experienced was participants not having a reminder 
form, clearly visible, in their hand-held maternity notes. Without 
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this form, midwives would not be aware of the participant’s 
involvement in the FFB study. Initially, distribution of these forms 
relied on participant attendance to the FFB clinic. Therefore, as 
mentioned earlier, problems were experienced as participants were 
either not given appointments to the clinic, or participants did not 
attend their appointment. This issue was addressed by obtaining 
ethical consent to contact participants by post, and forms were then 
sent out by post. This then relied on participants placing the forms 
within their notes themselves. The only opportunity for the 
candidate to ensure that the form was not only placed in the notes, 
but also clearly visible to the midwives, was on the coincidental 
chance that the candidate checked the ward at the same time as the 
participant was admitted. Many placentae were obtained through this 
method, however many were not, and thus data was lost. 
Problems encountered with actually physically obtaining the 
placentae, and notification of participant delivery to the candidate 
so that the subsequent anthropometric measurements could be 
performed, were mainly attributed to time constraints of the 
midwives. It was recognised that the midwives have a highly 
stressful and busy job, and when women’s lives may be in jeopardy, 
helping with a study may not be top of their priorities. Therefore, 
every effort was made, by the candidate, to check the maternity 
wards daily in case a delivery had occurred that they had not been 
notified about but, due to prior commitments, such as laboratory 
work, this did not occur at the same frequency or time each day, and 
thus due to swift discharge times, participants, and their infants, 
were missed.  
Also there was no policy outlined for when the candidate was 
unavailable to measure a neonate. Despite the candidate’s best 
efforts, there were several occasions when this was unavoidable, and 
therefore with no alternative, neonatal data was regrettably lost. 
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As a result of the multiple problems incurred by this study, a 
significantly smaller sample size was obtained. At the outset, it 
was hoped that one hundred and fifty placentae would be obtained 
from participants with a BMI of greater than thirty five. Therefore, 
with only seventy four placentae obtained, the study has half the 
number of placentae that were initially expected. However, it should 
be remembered that the FFB study is a two year project and there is 
still a further twelve months for obtaining placentae and neonatal 
anthropometric measurements. Thus, it is speculated that the desired 
number will be achieved by the end of the two year period. However, 
even with half the expected final sample size, many of the results 
shown were significant, which is promising for when the final 
statistical analysis is performed.  
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4.6. Future work 
4.6.1. Within this study 
Previous studies examining immunohistochemistry have revealed that 
the syncytium is a source of IL-1β and IL-6, and Hofbauer cells have 
also been shown to exhibit signals for both cytokines90. From this 
study, no conclusions can be drawn about which cell types are 
contributing to the intra- and extra-cellular cytokine 
concentrations. Therefore, the next step in this study is 
immunohistochemical staining of the incubated placental tissue 
fragments. This is scheduled to be conducted over the next coming 
year.  
Also future work is planned for investigating macrophages within the 
placentae of obese participants. This hopes to support, or dismiss, 
the finding by Challier et al that there are increased numbers of 
macrophages within the placentae of obese women. Immunohistochemical 
staining for CD14 and CD68, both macrophage markers, has already 
begun and image analysis is scheduled over the next coming months. 
If raised numbers of macrophages are found within the placentae of 
obese participants, further work is planned to determine whether 
these macrophages contribute to elevated cytokines witnessed in the 
placentae of obese participants. This will again be conducted by 
immunohistochemical staining over the course of the next year, once 
image analysis of the CD14 and CD68 stained slides has been 
completed. 
4.6.2. Beyond this study 
To elucidate the mechanisms leading to, not only increased foetal 
growth, but also decreased foetal growth, in association with 
obesity, future research needs to segregate uncomplicated maternal 
obesity from obese mothers with GDM. Further segregation of neonates 
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into increased, normal, and decreased adiposity then needs to be 
done. It would then be interesting to conduct in-depth maternal, 
neonatal, and placental analysis within the different categories. In 
each category the following variables could be examined; maternal 
circulating hormonal and cytokine levels; neonatal anthropometry; 
placental histopathology; placental responsiveness to factors raised 
in obesity and the effect this has on cytokine production and 
nutrient transporter activity; and finally immunohistochemistry on 
the placental explants. This would give a detailed analysis of the 
individual mechanisms resulting in each of the neonatal outcomes, 
and then comparisons between the mechanisms could then be made. 
Without doing so there are too many confounding factors which stand 
to conceal important associations. 
Future research could also be conducted on the role of leptin in 
foetal growth. As mentioned earlier, leptin may be involved in 
cellular regulation opposed to overall foetal growth. It would 
therefore be particularly intriguing to perform a prospective 
longitudinal study investigating the relationship between maternal 
circulating leptin levels and the chance of offspring developing 
metabolic syndrome, and determine whether leptin has any effect on 
the long term outcome of the infant. 
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4.7. Conclusions 
Maternal obesity and increased weight gain during pregnancy have 
been previously shown to be associated with unfavourable neonatal 
outcomes, with some neonates achieving sub-optimal growth and others 
achieving excessive growth.  Many factors are believed to be 
implicated in the development of these outcomes; however, they are 
far from understood. Maternal obesity leads to alterations within 
the placenta, instigating a pro-inflammatory state, characterised by 
an excessive accumulation of macrophages, which is not apparent on 
morphological examination. This pro-inflammatory state is unlike 
acute inflammation, which is characterised by neutrophil 
accumulation, suggesting that a similar situation, as occurs in WAT, 
may also be occurring within the placenta. More importantly, these 
placental alterations are not only thought to cause short term 
neonatal problems, but also cause detrimental changes to the long 
term development of the offspring, impacting upon its entire 
lifetime.  
 
Therefore, areas for research may be into the association of 
nutritional intake on foetal outcome, and a possible intervention 
could, perhaps, be the implementation of a specific diet tailored 
for obese pregnant women. This could potentially limit excessive 
weight gain during pregnancy and reduce the risks to the developing 
foetus. The implementation of a tailored diet will, however, involve 
a drastic lifestyle change for the women, which will be notoriously 
hard to enforce and monitor. However, it is hoped that as more and 
more research is conducted into the adverse foetal consequences of 
maternal obesity, the associated risks will become more publicised. 
With increased publication, it is anticipated that this will 
encourage women to lose weight prior to conception of a planned 
pregnancy. 
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                                                                                          FFB Placental Controls info sheet, version 2 (May 2009) 
 
Liverpool Women’s Hospital 
Crown Street 
Liverpool L8 7SS 
 Tel 0151 702 4101 
 
 
Principal Investigators: Dr Siobhan Quenby & Dr Andrew Weeks 
 
 
           INFORMATION SHEET (PLACENTAL CONTROLS) 
 
 
We would like to invite you to take part in a research study.  
 
Please take time to read this information carefully and discuss it with others if you like.  
 
Ask us if there is anything that is not clear. 
 
Take time to decide whether or not you wish to take part. 
 
Why are we doing this research? 
 
Fit for Birth is a large study in which 3000 overweight women are being recruited. It will examine the 
effect of the mother’s weight on pregnancy and its outcome.  
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As part of that study after delivery we will be examining the placentas of a few women who are very 
overweight. We want to compare these placentas with women with a normal body weight – and this 
is where you come in. 
 
We would like to take your placenta away for examination after you deliver. The placenta will be cut 
up in the laboratory and looked at under the microscope to see if there are any abnormalities. The 
health of your placenta (and the rest of the placentas from the ‘normal weight group’) will be 
compared with those from the overweight group to see the effect of body weight. 
 
Why have I been chosen? 
 
You have been chosen to take part because you have a normal body mass index. 
 
Do I have to take part? 
 
No, it is up to you to decide. You are still free to change your mind at any time and without giving a 
reason. This would not affect your care – you would receive normal care. 
 
What will happen if I take part? 
 
You will notice no difference to your care. After your placenta is delivered, instead of being disposed 
of, it will be taken away to a laboratory for examination. Parts of the placenta may be kept  
for future reference. The remainder will be disposed of in the normal way. A special trained midwife 
would like to measure round your baby’s arm and also to measure the thickness of a fold of skin. 
 
What are the possible disadvantages of taking part? 
None. 
 
What are the possible advantages of taking part? 
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There are a few placental abnormalities that are important for the management of future 
pregnancies. These are very rare, but would be picked up at this examination. If we did find one of 
them, then we may be able to improve the outcome of any future pregnancies that you have. 
 
What if something goes wrong? 
 
In the unlikely event of anything going wrong with the treatment, or if you wish to complain, or have 
any concerns about the way you have been approached or treated during the course of this study, 
then the normal NHS complaints system will be available to you. If you are harmed due to 
someone’s negligence, then you may have grounds for a legal action.  There are, however, no special 
compensation arrangements in place in case of problems with the research.  
 
Will my details be kept confidential? 
 
All information that is collected about you during the course of the research will be kept 
confidential. The completed forms with your name on them will be kept in the central trial office in 
Liverpool and your name will be removed before the data is transferred to the computer database 
for analysis. If you agree to take part in the research, the researching doctors may look at any of 
your medical records to analyse the results.  They may also be read by people from regulatory 
authorities to check that the study is being carried out correctly.   
 
What will happen to the results? 
 
The study is planned to finish in late 2010.  The results will then be analysed and published in a 
medical journal.  You will not be identified in any publication.  If you would like to receive a copy of 
the final publication, then please indicate this on the consent form. 
 
Who is funding the research? 
 
The research is funded by Liverpool Primary Care Trust through MerseyBeat, a project of the 
University of Liverpool. The doctors conducting the research are not being paid any extra for it.   
 
Who has approved the study? 
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This study has been approved by the Liverpool Women’s Hospital Research and Development 
Department, and the Liverpool Adult Research Ethics Committee. 
 
Contact for Further Information 
For further information about the study please contact: 
 
Mr David Rycroft - Fit for Birth administrator,  
School of Reproductive and Developmental Medicine, Liverpool Women’s Hospital, Crown 
Street, Liverpool L8 7SS  
Tel: 0151 702 4179; e-mail David.Rycroft@liv.ac.uk 
OR go to our website at www.fitforbirthstudy.org.uk 
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Liverpool Women’s Hospital 
Crown Street 
Liverpool L8 7SS 
 Tel 0151 702 4101 
 
 
Principal Investigators: Dr Siobhan Quenby & Dr Andrew Weeks 
 
 
Patient Hospital Number: 
 
                           CONSENT FORM (PLACENTAL CONTROLS) 
 
 
Title of Project: Fit for Birth: a prospective cohort study  
 
Name of Researchers:  Dr Siobhan Quenby & Dr Andrew Weeks, University of Liverpool 
 
Please initial box 
 
1. I confirm that I have read and understand the information sheet dated May 2009. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any  
time without my medical care or legal rights being affected. 
 
Consent 2 
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3. I understand that sections  of my medical notes and data collected during the  
             study may be looked at by individuals from the University of Liverpool, 
             from regulatory bodies or from the NHS Trust where it is relevant to my taking part 
             in this research. I give permission for these individuals to have access to my, and  
             my baby’s, records. 
 
4. I agree to take part in the above study.  
 
5.          I agree to my GP being informed of my participation in the study. 
 
6.  Do you wish to receive a final copy of the results when they are published?           Yes / No 
 
 
 
 
_________________________  ___________  _______________________ 
Name of Patient    Date    Signature 
 
 
 
________________________  ____________  _______________________ 
Researcher    Date   Signature 
 
 
 
1 copy  to be kept with handheld notes, 1 copy to be kept in brown hospital notes 
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This Patient has consented for the ‘Fit for 
Birth’ Study: 
PLEASE SEND 
PLACENTA FOR 
HISTOLOGY 
Please text/leave voicemail:  
immediately to notify the researcher that the 
woman has delivered, e.g. Sarah Jones has 
delivered on Mat 1, as the baby also requires 
measuring for the study (Call anytime - 24/7). 
The relevant histology form is attached behind. 
Thank you for your help  
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Appendix III 
Covering Letter to Patients with FFB Reminder Form 
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30th  June 2010 
 
 
Dear  
I am writing to you with regard to the ‘Fit For Birth’ study that you consented to at the beginning of 
your pregnancy. As part of the study we would like to examine your placenta once your baby has 
been born. In order to help us obtain your placenta for examination please place the two enclosed 
forms at the very front of your hand-held notes. These forms will highlight to your midwife that you 
are part of the ‘Fit For Birth’ study and that your placenta requires sending for histology. Having your 
placenta sent for histology will not affect your treatment during your stay in hospital and your 
participation within this study is greatly appreciated. 
 If, however, you have changed your mind and no longer wish to have participate in the ‘Fit For Birth’ 
study then do not place these forms with your notes and your placenta will not be sent for 
examination. 
Thank you very much for cooperation with our study, 
Yours Sincerely, 
The Fit for Birth Team 
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Appendix IV 
FFB Reminder Poster to the Midwives 
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THIS PATIENT HAS CONSENTED 
FOR THE ‘FIT FOR BIRTH’ STUDY 
PLEASE SEND 
PLACENTA FOR 
HISTOLOGY 
PLEASE QUOTE: ‘FIT FOR 
BIRTH STUDY’ AS 
REASON FOR HISTOLOGY 
Thank you for your help 
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NOTE – Appendix V-VIII are not available electronically as part of 
this thesis. 
 
Appendix V 
FFB Histology Form 
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Appendix VI 
Technique used for Neonatal Skin fold thickness 
measurement using Harpenden Callipers 
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Appendix VII 
Control Patient Information Sheets 
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Appendix VIII 
    Control Consent Forms 
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Appendix IX 
Bulk Birth Weight Centile Calculator 
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Example of bulk birth weight centile calculator used. 
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Appendix X –  
Protocols for Laboratory work 
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o Advance Preparation: 
 
The following items were prepared in advance of a placenta arriving 
at the laboratory for culturing: 
1. For sterilisation, the following items were autoclaved at 121oC 
for fifteen minutes: 
i. Glass dish 
ii. 3 sets of forceps 
iii. 3 sets of scissors 
iv. 1ml pipette tips 
v. 250µl pipette tips 
2. 10M, 2M and 3M NaOH: 
- 10M = 100ml distilled H20 + 40grams NaOH 
- 2M = 200ml distilled H20 + 20 grams NaOH 
- 0.3M = 1 litre distilled H20 + 12grams NaOH 
3. 10mM HCl: 
- NB. Laboratory stock of HCl = 10M solution 
- 10mM = 50 µl stock HCl + 50ml distilled H20 
4. 20mM Tris: 
- 20mM Tris = 100ml distilled H20 + 0.24grams Trizma base. 
- Adjust to pH 8.0 with HCl. 
- Filter prior to use. 
5. Primary Buffering solution (PBS) / 0.1% Bovine serum albumin 
(BSA): 
- 1 litre of PBS = NaCl  8 g 
KCl  0.2 g 
Na2HPO4.2H2O 1.5 g 
KH2PO4  0.2 g 
- Dissolve and adjust to pH 7.4 with 2M NaOH. 
- Defrost 10% BSA from -20 C freezer. 
- In a sterile universal tube prepare: 
- 20 ml PBS / 0.1% BSA = 200 µl 10% BSA + 19.8 ml PBS. 
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- Mix by inversion / vortex and store at 4 C. 
- Filter prior to use. 
 
 
6. 5 litres 5mM Tyrodes solution: 
- 5 litres Tyrodes solution = 135 mM NaCl   39.45 g 
 5 mM KCl   1.86g 
1.8 mM CaCl2 (2H2O) 1.32g 
1 mM MgCl2(6H2O)  1.02g 
10 mM HEPES   11.92g 
5 mM Glucose  4.5g 
- Dissolve in 1-2 litres water, and adjust pH 7.4 with 10M NaOH. 
- Add water to make up to 5 litres. 
- Store in 1 litre glass bottles and filter prior to use. 
7. 1 litre of each; 15mM and 25 mM glucose Tyrodes: 
- First 2 litres of Tyrodes solution was made up =  
135 mM NaCl   15.78g 
5 mM  KCl   0.74g 
1.8 mM CaCl2 (2H2O) 0.53g 
1 mM  MgCl2(6H2O)  0.41g 
10 mM  HEPES   4.77 g 
- Dissolve in 2 litres dH2O, and transfer to 2 1litre bottles. 
- Label 1 bottle 15 mM and add 5.4 grams of glucose, dissolve by 
stirring with a magnetic stir bar, and adjust to pH 7.4 with 10M 
NaOH. 
- Label 1 bottle 25 mM and add 9 grams of glucose, dissolve by 
stirring with a magnetic stir bar, and adjust to pH 7.4 with 10M 
NaOH. 
- Filter prior to use. 
8. Stimulant preparation: 
a. Leptin - Only one working stock concentration was needed 
for leptin.  
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- Leptin (398-LP) was supplied by R&D Systems as a lyophilized 
powder and was stored at -20°C to -70 C.   
- It was reconstituted at a concentration of 1mg/ml in sterile 20 
mM Tris-HCl = 1ml 20 mM Tris-HCl to the 1 mg leptin supplied.  
- pH was adjusted to 8.0, using 10M NaOH 
- After reconstitution 1 mg/ml leptin is stable for 1 month at 2-8 
°C and 3 months at -20 to -70°C.  Freeze thaw was avoided. 
- Working stock solution of 40 µg/ml was prepared = 
20 µl 1mg/ml leptin + 480 µl diluent. 
- It was stored in 25 µl aliquots at -20°C to -70 C. 
b. TNF-  - Three working stock concentrations were required 
for TNF- ; 12 µg / ml, 4 µg/ml, 0.4 µg / ml.  
- TNF-  (210-TA) was supplied by R&D Systems as a lyophilized 
powder and was stored at -20 to -70 C. 
- It was reconstituted at a concentration of 100 µg / ml in sterile 
filtered PBS / 0.1% BSA, by adding 100 µl PBS / 0.1% BSA to the 
10 µg TNF-  supplied. 
- After reconstitution 100 µg/ml TNF-  is stable for 1 month at 2-
8 C and 3 months at -20 to -70°C.  Freeze thaw was avoided. 
- Working stock solutions of the following concentrations were 
prepared: 
12 µg/ml TNF- =90µl 100 µg/ml TNF- +660 µl sterile filtered PBS/0.1% 
BSA. 
4 µg/ml TNF- =150 µl 12 µg/ml TNF- +300 µl sterile filtered PBS/0.1% 
BSA. 
0.4 µg/ml TNF- =50 µl 4 µg/ml TNF- +450 µl sterile filtered PBS/0.1% 
BSA. 
- 3 aliquots of each concentration were stored in 40 µl aliquots 
and the remainder in 25 µl aliquots at -20°C to -70 C.   
c. Insulin – four working stock concentrations were needed 
for insulin; 400nM, 40 nM, 40 µM and 400µM. 
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- Insulin (I0259) was supplied by Sigma-Aldrich as a powder 
and was stored at -20°C.   
- It was reconstituted at a concentration of 20 mg/ml in 10 mM HCl 
=  
250 mg insulin + 12.5 ml 10 mM HCl. 
- A working stock solution of concentration 230µg/ml was prepared:  
10 µl 20 mg/ml stock solution + 850 µl sterile filtered PBS/0.1% 
BSA. 
- Further working stock solutions of the following concentrations 
were prepared by serial 10x dilution:  
23 µg/ml = 100µl 230µg/ml stock + 900 µl sterile filtered PBS/0.1% 
BSA 
2.3 µg/ml = 100 µl 23 µg/ml stock + 900 µl sterile filtered PBS/0.1% 
BSA 
0.23 µg/ml= 100 2.3µl µg/ml stock + 900 µl sterile filtered 
PBS/0.1%BSA 
- Each concentration was stored in labelled 25 µl aliquots at -
20°C.  
 
o Advance Preparation for Each Placenta Received: 
1. 2 sets of scintillation vials were labelled; both sets were 
labelled 1-11. One set was for protein assays to be performed 
on, and the second set was for immunohistochemistry to be 
performed on. They were placed in two separate racks.  
- 4ml of filtered control Tyrodes solution was pipetted into vial 1 
and 4-11 and recapped.  
- 4ml of 15mM Tyrodes solution was pipetted into vials labelled 2 
and recapped. 
- 4ml of 25mM Tyrodes solution was pipetted into vials labelled 3 
and recapped. 
- All vials were placed in the fridge. 
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2. A further set of scintillation vials were labelled 1-11. Each 
vial was also labelled with a ‘W’, to denote that it contained 
water, not Tyrodes solution. 
- Approximately 36 ml of distilled H20 was fast pipetted in a 
sterile universal tube. 
- 18µl of protease inhibitor cocktail (PI) was added to the 
distilled H20 (10µl PI per 20ml distilled H20). The solution was 
inverted to mix. 
- 2ml of the distilled H20/PI was pipetted into each scintillation 
vial and recapped. 
- All vials were placed in the fridge. 
NB. This was only done on the day of culturing to avoid 
PI degradation. 
3. A further set of scintillation vials were then labelled 1-11. 
Each vial was also labelled with ‘NaOH’, to denote that it 
contained NaOH, not Tyrodes solution or water. 
- Approximately 10ml of 0.3M NaOH was pipetted into each vial and 
recapped. 
4. 160 microcentrifuge tubes were labelled using the following 
coding: 
- Letter – denoted the order in which placentae were received (A-M) 
e.g. 1=A, 2=B etc. 
- Number – corresponded to stimulant condition (1-11) – see 
stimulant table above. 
- E – denoted that the supernatant was extracellular – 6 tubes were 
labelled per stimulant 
- I – denoted that the supernatant was intracellular – 4 tubes were 
labelled per stimulant denotes intracellular 
NB. Only tubes for the first set of vials were labelled e.g. 
1-11, 11x6 extracellular and 11x4 intracellular. No 
microfuge tubes were needed for the second set. 
5. 11 sterile bijou tubes were labelled with the date, 
corresponding placental letter, and numbered 1-11. They were 
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filled with approximately 5ml of 4% neutral buffering formalin 
(NBF).           
6. The microbiological safety class II (MCII) cabinet was cleaned 
using 1:100 TriGene Advance solution and dry with absorbent 
towels. 
 
On the day of culturing, prior to receiving the placenta: 
1. The water bath switched on to heat up to 37°C. The water level 
was checked and filled up using distilled water if it was 
deemed too low. 
2. The following items were placed on a clean plastic tray in the 
MCII cabinet: 
- Sterile glass dish 
- 2 sets of sterile forceps 
- 2 sets of sterile scissors 
3. The following items were placed within the MCII cabinet but 
set to one side: 
- 2x10cm Petri dishes containing filtered 5mM Tyrodes solution. 
- 1x20cm Petri dish containing filtered 5mM Tyrodes solution. 
- Both sets of labelled scintillation vials containing Tyrodes 
solution. 
- 3 sterile pots containing PBS labelled 1, 2, 3. 
- Sharps discard pot containing 1:100 TriGene Advance Solution. 
- Defrosted stimulants placed on ice. 
4. An equipment decontamination container was prepared (Large 
plastic container filled to 50% capacity with 1% Virkon). 
 
o Villous tissue Preparation: 
1. Once the placenta was received from theatre, it was placed in 
the sterile glass dish. 
2. The maternal and foetal aspects of the placenta were 
photographed prior to commencing excision of tissue. 
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3. The placenta was positioned with the maternal aspect facing 
upwards. 
4. 3x1cm3 full thickness samples were cut from the placenta. The 
samples were cut from 3 different areas of the placenta to 
ensure a representative sample was taken. Samples were cut from 
the belly of a cotyledon, avoiding the area directly below the 
cord and the periphery.  
5. The samples were placed in the pot 1 containing PBS. They were 
then subsequently placed in pot 2, and then pot 3. This was to 
remove any excess blood from the samples. 
6. The 2 samples were then placed in the two 10cm Petri dishes 
(the third remained in the PBS to avoid drying out). 
7. Using the forceps and scissors the chorionic plate and the 
decidual edge were dissected from the remaining villous tissue. 
8. Each sample was then dissected into approximately 0.25 cm3 
fragments which were then placed in the 20cm Petri dish. This 
was to ensure that all the fragments from the three samples 
were mixed. 
9. 6 fragments were then placed in each scintillation vial. 
10. 10 µl of the working stock solutions of the stimulants were 
then added to the appropriate scintillation vials (according to 
the stimulant table). 
11. The vials were then placed, uncapped, in the shaking water-bath 
for 3hours. 
12. The placenta was then placed back in the histology bucket and 
returned, along with a completed histology form, to delivery 
suite to be sent for histology. 
13. After 3 hours, the vials were removed from the water-bath. 
14. Using forceps, the fragments from the first set of 
scintillation vials (1-11) were quickly placed into the 
corresponding scintillation vials containing 2ml distilled 
H2O/PI and recapped.  
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15. The scintillation vials containing the supernatant were then 
placed on ice. 
16. The supernatant from each vial was then aliquotted into the 
corresponding, labelled microfuge tubes, NB. Also labelled ‘E’ 
(extracellular). Approximately 660µl of supernatant was placed 
in each microfuge tube. Tubes were placed on ice until all 
tubes had been aliquotted. This was to avoid degradation of 
cytokines within the supernatant. 
17. Aliquots were stored at -80 C. Freezer plans were then filled 
in. 
18. The fragments from the second set of scintillation vials were 
placed into the bijou tubes containing 4% NBF. The bijou tubes 
were then placed in the fridge overnight to fix in the NBF.  
19. The scintillation vials now containing the fragments were then 
incubated for  18 hours at 4 C.   
20. After 18-20 hours, the fragments were then removed and placed 
in the scintillation vials labelled 1-11 ‘NaOH’, containing 
10ml of NaOH. The vials were recapped and placed in the water-
bath at 37 C  6 h.  
21. The vials containing the supernatant were each placed on ice 
after the fragments had been removed. 
22. The supernatant from each vial was then aliquotted into the 
corresponding, labelled microfuge tubes NB. Also labelled ‘I’ 
for intracellular. Approximately 500 µl of supernatant was 
placed in each microfuge tube. Tubes were placed on ice until 
all tubes had been aliquotted. This was to avoid degradation of 
cytokines within the supernatant. 
23. Aliquots were stored at -80 C. Freezer plans were then filled 
in. 
24. After the 6 hour incubation of the scintillation vials 
containing the 0.3M NaOH were placed in the fridge. 
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o Methodology for Processing of Fixed Samples and Wax 
Embedding 
Due to time constraints on the candidate, the wax embedding was 
conducted by Lisa Heathcote and Jo Drury. 
1. After the fragments in the bijou tubes had fixed in the 4% NBF 
for 24 hours, samples were placed in mesh bags (in 2 groups of 
3 fragments) and placed in corresponding, labelled plastic 
cassettes. 
2. The cassettes were then put in a processing basket and placed 
in the Shandon Citadel Processor to be dehydrated, cleared and 
impregnated with paraffin wax. In summary the following process 
is followed: 
- 4% formalin in neutral buffer 45 
minutes 
- 60% Ethanol  1 hour 
- 70% Ethanol  1 hour 
- 90% Ethanol   1 hour 
- 100% Ethanol   1 hour 
- 100% Ethanol   1 ½ hours  
- 100% Ethanol   2 hours 
- Xylene 1  1 hour  
- Xylene 2  1 ½ hours  
- Xylene 3  2 hours  
- Wax 1  2 ½ hours  
- Wax 2  3 ½ hours 
3. Once finished, the blocks were placed into heated reservoir in 
the embedding machine. 
4. A metal mould was then taken from the heated unit and half 
filled with wax. 
5. A cassette was then taken and placed on the heated area by the 
wax tap to prevent solidification of the wax. 
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6. The sample was then removed from the cassette and transferred 
to the wax-filled mould using hot forceps. 
7. The mould was then transferred to the cold area of the 
embedding unit. Hot forceps were then used to position the 
tissue in the mould. Once position the sample was covered with 
a plastic cassette with the label facing upwards. 
8. The sample was then topped up with wax, and placed on cooling 
block. 
9. After 30 minutes the cassette was removed from the metal 
mould. 
10. All the blocks were then stored in at room temperature. 
 
o ELISA Methodology - Advance Preparation: 
1. Antibodies: 
- R&D Systems supplied the ELISA duo-sets for all the cytokines 
(catalogue reference DY201 (IL-1β), DY206 (IL-6) and DY208 (TNF-
α)). 
- Each duoset contained a bottle of:  
a) Monoclonal capture antibody: 
- Capture antibodies for all cytokines were 
reconstituted in 1ml sterile PBS to give a stock 
concentration of 720µg/ml. 
- Capture antibodies can be stored for 60 days at 
4oC or frozen at -20°C to -70°C for 6 months. 
b) Secondary Polyclonal Biotinylated goat anti-human 
antibody: 
- Secondary antibodies for IL-6 and IL-1β were 
reconstituted in 1ml PBS/1% BSA, giving a stock 
concentration of: IL-
µg/ml.  
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-Secondary antibody for TNF-α was reconstituted in 
1ml of PBS/0.1% BSA giving a stock concentration of 
54 g/ml. 
- Secondary antibodies can be stored for 60 days at 
4°C or frozen at -20°C to -70°C for 6 months. 
c) Detection agent (Streptavidin horseradish peroxidise 
(HRP)) 
d) Pre-determined concentrations of cytokines to be used 
for preparing the standard curves: 
- IL-1β stock concentration = 40ng/ml 
- IL-6 stock concentration = 45ng/ml 
- TNF-α stock concentration = 310ng/ml 
(TNF-α was reconstituted in 0.5ml of PBS/0.1% BSA, 
giving a diluted concentration of 31ng/ml). 
The following solutions were made up prior to commencing an ELISA 
run: 
1. 5litres of PBS: 
- 5 litres of PBS = NaCl  40 g 
KCl  1.0 g 
Na2HPO4.2H2O 7.5 g 
KH2PO4  1.0 g 
- Dissolve in 1 litre of distilled H2O and adjust to pH 7.4 
with 2M NaOH. 
- Make up volume to 5 litres using distilled H2O 
 
2. PBS/1%BSA: 
- Defrost 10% BSA from -20 C freezer. 
- In a sterile universal tube prepare: 
 20 ml PBS/1% BSA = 2ml 10% BSA + 18 ml PBS. 
 Mix by inversion / vortex. 
 
3. PBS/0.1% BSA: 
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- Defrost 10% BSA from -20 C freezer. 
- In a sterile universal tube prepare: 
 20 ml PBS/0.1% BSA = 200 µl 10% BSA + 19.8 ml 
PBS. 
 Mix by inversion / vortex. 
 
4. Wash buffer: 
- Approximately 2 litres should be made up prior to each 
run 
- 2 litres of wash buffer= 
2ml of Tween 20 + 2litres of PBS 
- Store at room temperature. 
 
5. Blocking buffer: 
= 90ml PBS + 10ml 10% BSA + 5g sucrose + 250µl 20% sodium azide 
- Store in the fridge at 4oC in an opaque glass bottle. 
 
4.7.1.1. The ELISA Run: 
This method has been written as if three plates were running 
simultaneously, one for each of the cytokines assayed. 
NB. 
The diluent used throughout the run for IL-6 and IL-1β was PBS/1% 
BSA 
The diluent used throughout the run for TNF-α was PBS/ 0.1% BSA 
 
Initially, the diluent for TNF-α contained 0.05% Tween 20, however 
this was omitted after several unsuccessful ELISA runs using this 
diluent. 
1. A plan detailing where the samples to be assayed were to be 
placed on the microtiter plate was prepared prior to the ELISA 
run. Samples were run in duplicate and an average of the two 
concentrations was taken. 
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2. Antigen coating the plates: 
- The primary antibodies for each cytokine were prepared: 
- For each cytokine:  
55µl of capture antibody was added to 9945µl of 
appropriate diluent. 
- (Final concentrations: IL-6 = 200ng/ml, IL-1β = 100ng/ml 
and TNF-α = 4 g/ml). 
- 3 ELISA plates were labelled; IL-1β, IL-6 and TNF-α. 
- Each plate was then coated with 100 µl per well of primary 
antibody and covered with plate sealer. 
- The plates were then incubated at room temperature 
overnight. 
3. The plates were then washed using a wash bottle filled with wash 
buffer. The wells were filled forcefully and once the entire 
plate was full, the buffer was decanted into the sink and the 
blotted vigorously on paper towels. This was repeated 3 times in 
total. 
4. The wells were then filled with 300 µl of blocking buffer (which 
was at room temperature) and incubated for 1 hour at 37ºC in a 
Dynatech Varishaker Incubator. 
5. The samples to be assayed were then removed from the freezer and 
allowed to defrost in ice. 
6. A separate standard curve for each cytokine to be assayed was 
prepared: 
 IL-1β: 
The highest concentration of IL-1β on the standard curve was 
500pg/ml= 
10µl of the supplied IL-1β standard stock + 990 µl PBS/1% BSA  
All other standard curve concentrations were then prepared by 
serial dilution using PBS/1% BSA as follows: 
Code for 
plate plan 
Final concentration 
of IL-1β(pg/ml): 
Volume of previous 
IL-1β standard curve 
Volume of 
PBS/1% BSA 
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concentration (µl) (µl) 
S1 500.00 n/a 990 
S2 250.00 300 300 
S3 125.00 300 300 
S4 62.50 300 300 
S5 31.25 300 300 
S6 15.63 300 300 
S7 7.81 300 300 
S8 3.91 300 300 
Table 4.1 - Table to show how standard curve for IL-1B was produced. 
 
 IL-6: 
The highest concentration of IL-6 on the standard curve was 
600pg/ml= 
10µl of the supplied IL-6 standard stock + 740µl 
PBS/1% BSA 
All other standard curve concentrations were then prepared by 
serial dilution using  PBS/1% BSA as follows: 
Code for 
plate plan 
Final Concentration 
of IL-6 (pg/ml): 
Volume of previous 
IL-6 standard curve 
concentration (µl) 
Volume of 
PBS/1% BSA 
(µl) 
S1 600 n/a 740 
S2 300 300 300 
S3 150 300 300 
S4 75.0 300 300 
S5 37.5 300 300 
S6 18.75 300 300 
S7 9.38 300 300 
S8 4.69 300 300 
 TNF-
α: 
The highest concentration of TNF-α on the standard curve was 
1000pg/ml= 
37µl of the supplied TNF-α standard stock + 963µl 
PBS/0.1% BSA 
Table 4.2 - Table to show standard curve for IL-6 was prepared. 
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All other standard curve concentrations were then prepared by 
serial dilution using PBS/0.1% BSA as follows: 
 
NB. Blank diluent was used as S0 for all cytokines. 
 
7. 1:2 dilutions of the extracellular supernatants were prepared = 
150µl sample + 150µl diluents 
This was done because when samples were run undiluted the 
generated cytokine concentration was greater than the highest 
concentration on the standard curve i.e. ‘>max’ 
8. 1:4 dilutions of the intracellular supernatant were prepared =  
60µl sample + 180µl diluents 
 The reasoning for this was the same as for dilution of 
extracellular supernatant. 
NB. All the samples were vortexed thoroughly prior to use to ensure 
a representative sample was used for the ELISA. 
9. After one hour, the plates were removed from the incubator and 
washed three times with wash buffer (repeat step 3). 
10. 100 µl of each standards, sample or diluent was pipetted into the 
plate according to the plate plans. The plates were then 
incubated for 1 hour at 37ºC in a Dynatech Varishaker Incubator. 
Code for 
plate plan 
Final Concentration 
of TNF-α (pg/ml): 
Volume of previous  
TNF-α standard curve 
concentration (µl) 
Volume of 
PBS/1% BSA 
(µl)  
S1 1000 n/a 963 
S2 500 300 300 
S3 250 300 300 
S4 125 300 300 
S5 62.5 300 300 
S6 31.25 300 300 
S7 15.6 300 300 
Table 4.3 - Table to show how standard curve for TNF-a was prepared. 
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11. The secondary antibodies were then prepared by performing a 1:180 
dilution =  
55µl antibody + 9945µl diluent 
 The final concentrations of each cytokine were as such: 
IL-1β = 100ng/ml 
IL-6 = 200ng/ml 
TNF-α = 0.3µg/ml 
12. After one hour, the plates were removed from the incubator and 
washed three times with wash buffer (repeat step 3). 
13. 100 µl of the secondary antibody was then added to each well and 
covered. The plates were then incubated for 1 hour at 37ºC in a 
Dynatech Varishaker Incubator. 
14. The plate plan was then entered onto the Multiskan Ascent plate 
reader. Appropriate sample identification and any dilutions were 
inputted onto the plate plan and saved under a new file name. 
15. A 1:200 dilution of the detection agent, Streptavidin HRP, was 
then prepared =  
50µl Streptavidin HRP + 9950µl diluent 
16. After one hour, the plates were removed from the incubator and 
washed three times with wash buffer (repeat step 3). 
17. 100 µl of Streptavidin/HRP was added to each well and incubated 
for 30 minutes at room temperature. 
18. After 30 minutes, the plates were removed from the incubator and 
washed three times with wash buffer (repeat step 3). 
19. 100µl of TMB/H2O2 was added to each well. The solution was 
inspected prior to use and was discarded if it already appeared 
blue. The plates were then incubated, in the dark, at room 
temperature, for 6-7 minutes, or until there was an adequate 
colour gradient along the standard curve. 
20. 50 µl of 1M H2SO4 was then added to each well to inhibit any 
further enzyme activity. 
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21. The plate was then placed on the plate reader, ensuring there was 
no cover on the plate. 
22. The optical density of the wells was then read between the 
intensities of 450nm and 540nm. 
23. A graph, plotting cytokine concentration against net absorbance, 
was then generated, giving a standard curve. A line of best fit 
was then applied and the concentration of the cytokine being 
assayed within each sample was automatically generated using the 
standard curve. 
24. If any results were ‘>max’ i.e. the concentration of cytokine 
within that well exceeded the highest concentration on the 
standard curve, then, if possible, this result was repeated on 
another run. 
25. If any results were ‘<min’ i.e. the concentration of cytokine 
within that well fell below the lowest concentration on the 
standard curve, then, if possible, this result was repeated, 
undiluted, on another run. 
 
o Protein Concentration Analysis: 
The following solutions were made up prior to commencing a Bradford 
Protein Assay run: 
1. 900ml of 0.3M HCl = 
 27ml 10M HCl + 873ml distilled H2O  
 
2. 1 litre of 0.3M NaOH = 
12g NaOH + 1 litre distilled H2O 
 
3. 400 µl 0.25mg/ml BSA: 
- Stock BSA concentration = 2mg/1ml 
- 400 µl 0.25mg/ml BSA =  
50µl Stock BSA + 350µl 0.3M NaOH 
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- Final concentration of standard solution = 0.25mg/ml 
(1:8 dilution). 
 
4.7.1.2. The Bradford Protein Assay Run: 
1. A plan detailing where the samples were to be placed on the 
microtiter plate was prepared prior to the run. Samples were run 
in duplicate and an average of the two concentrations was taken. 
As there are only eleven samples per placenta, two placentae can 
be assayed simultaneously. 
2. A standard curve was then prepared as follows: 
 
Code used on 
plate plan 
Final Protein 
Concentration 
(µg/ml) 
Volume of 0.3M 
NaOH to be added 
(µl) 
Volume of 
0.25mg/ml BSA  
(µl) 
S0 0 100 0 
S1 12.5 95 5 
S2 62.5 75 25 
S3 125.0 50 50 
S4 187.5 25 75 
S5 250.0 0 100 
 
3. 20µl of each standard was then pipetted into each well 
according to the plate plan. 180µl of PBS was then added, 
giving a total volume of 200µl. 
4. 10µl of each sample was then pipetted into each well according 
to the plate plan. 190µl of PBS was then added, giving a total 
volume of 200µl. A smaller volume of sample was added, 
otherwise if 20µl was added the protein concentration 
generated was greater than the highest concentration on the 
standard curve i.e. ‘>max’ 
NB. All samples were vortexed prior to pipetting. 
5. 50µl of Bradford’s dye reagent (at room temp) was then added 
to each well.  
6. The plate plan was then entered onto the Multiskan Ascent 
plate reader. Appropriate sample identification and a dilution 
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factor of ten was applied to all samples as they were diluted 
in 10ml of NaOH. 
7. The microtiter plate was then placed on the plate reader and 
mixed for 30seconds. The plate was read at an absorbance of 
595nm. 
8. A graph, plotting protein concentration against net absorbance 
was then generated, giving a standard curve. A line of best 
fit was then applied and the concentration of protein within 
the samples was generated automatically using the standard 
curve.  
 
 
Figure 4-2 - A Typical standard curve for BSA 
and bovine gamma globulin (BGG) in the Pierce 
Coomassie Plus Protein Assay.
104 
9. Once the protein content of the villous tissue had been 
determined, the corresponding cytokine concentrations of the 
samples were divided giving a final cytokine concentration in 
pg/mg of protein. 
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Appendix XI 
Conclusion for PCT 
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This project was commissioned by Liverpool PCT with the following 
aims: 
1. ‘To determine the scale of the problem of obesity in 
pregnancy, in the Liverpool PCT area.’ 
2. ‘To generate information that can be used to develop 
services and plan further research.’ 
With respect to Aim two, the PCT were particularly interested in 
whether deployment of existing resources to obese women in pregnancy 
would be likely to impact on pregnancy outcomes. For example, if 
maternal weight change in pregnancy was clearly linked to foetal 
size it might be worth targeting dietetic advice to obese pregnant 
women. Although preliminary, the results presented here argue 
against the suggestion that redeployment of existing services to 
target obese pregnant women would improve neonatal outcomes. 
Firstly, in general obese pregnant women had recommended weight 
gains during pregnancy. Simple dietary modifications would be 
unlikely to be relevant. Secondly, neonatal body composition in this 
group was different from that observed in previous reports. 
Specifically, fat-free mass was higher in babies born to obese women 
compared to babies born to lean women. This suggests that women (and 
their foetuses) in Liverpool are nourished differently from women in 
previous cohorts. Interventions developed in other settings may not 
be directly applicable in Liverpool. Thirdly, obese pregnant women 
were taller than lean pregnant women. This may indicate that 
differences in nutrition between the two groups were longstanding. 
Height reflects growth until epiphyseal closure. Nutrition can 
influence height during childhood. Short term changes in nutrition 
may not affect maternal obesity. Fourthly, there is evidence that 
the state of chronic inflammation found in obesity is also found in 
pregnant obese women (albeit with some modification with respect to 
TNF-
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influence fetal nutrition (via an effect of IL-6 on System A). The 
inflammatory state appears to be a consequence of excess WAT which 
will be part of the baseline physiology when obese women become 
pregnant. Modifying this inflammatory process during pregnancy is 
not possible at present and defining suitable interventions will 
require a considerable research effort. Reducing the prevalence of 
obesity would be a more promising approach. Fifthly, even an 
observational study of obese pregnant women required considerable 
resources and effort. Supporting obese women during pregnancy would 
need considerable investment. 
This constellation of findings might help the PCT decide where to 
target their resources. Dietetic intervention in obese pregnancy 
would introduce women to that service but would be unlikely to 
affect neonatal outcomes. The PCT may have more appropriate 
priorities. Several of the findings of this project point to the 
benefits of reducing obesity before pregnancy. Thus population-level 
campaigns are more likely to succeed than campaigns targeted to 
pregnant obese women.  
In a world of imperfect public health information, the results 
presented here may contribute to rational resource allocation in the 
NHS as well as identify research questions. 
 
 
 
